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ABSTRACT 
Mycoplasma gallisepticum infection in chickens is associated with severe inflammation 
of the trachea, air sacs and lungs. M. gallisepticum cytadheres to the tracheal epithelium 
and mediates infiltration of macrophages, heterophils and lymphocytes to the tracheal 
submucosa but the molecular mechanisms underpinning the severe inflammatory 
response is not well understood. This research focuses on identifying how M. 
galisepticum and chicken tracheal epithelial cell (TEC) interaction might contribute to 
this response. The first study identified that M. gallisepticum lipid associated membrane 
proteins (LAMP)  from both virulent and non-virulent strains were able to up-regulate 
several inflammatory genes from tracheal epithelial cells both in vitro and ex vivo 
including, but not limited to IL-1β, IL-6, IL-8, IL-12p40, CCL-20 and NOS-2. However 
live virulent strains were significantly more efficient in not only up-regulating these 
genes to a greater extent but also differentially regulating several unique genes in TECs. 
The study also identified that M. gallisepticum LAMPs mediate the inflammatory gene 
up-regulation via TLR-2 ligation in an NF-κB dependent pathway. The second study 
identified, that interaction of a virulent strain with TECs leads to significantly more 
macrophage chemotaxis than a non-virulent strain. Macrophages upon co-culture with M. 
gallisepticum exposed TECs up-regulated expression of IL-1β, IL-6, IL-8, MIP-1β, 
CXCL-13, CCL-20 and RANTES. Interaction of Rlow with TECs enabled more efficient 
gene up-regulation from macrophages compared to Rhigh. Kinetic analysis of these genes 
identified the peak of expression of cytokine genes to be 6 hours reducing significantly 
thereafter, whereas expression of chemokine genes remained significantly above control 
level until 24 hours. These results further our understanding of molecular mechanisms 
leading to the severe inflammatory response observed during M. gallisepticum infection 
and suggest that interaction of M. gallisepticum with chicken tracheal epithelial cells play 
significant role in this process.  
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1.1 Introduction 
Mycoplasmas have gained considerable attention in the world of microbiology as 
pathogens to a wide array of hosts despite their extremely small size and limited 
biosynthetic capabilities. They are not considered as typical bacteria and belong to the 
class of ‘Mollicutes’ (in Latin: mollis, soft; cutis, skin) due to the lack of a rigid 
peptidoglycan cell wall. Other organisms including ureaplasmas, acholeplasmas, 
entomoplasmas, spiroplasmas, and phytoplasmas are also considered to be mollicutes [1]. 
Mycoplasma genome size ranges from as low as 580 kb in Mycoplasma genitalium [2] up 
to 1,380 kb for M. mycoides subsp. mycoides LC [1]. Their extremely small size enabled 
scientists to not only sequence the genomes, but also led to creation of a synthetic 
genome of Mycoplasma mycoides, and construction of a viable bacterium upon 
transplantation into Mycoplasma capricolum [3]. Mycoplasmas are phylogenetically 
linked to gram positive bacteria and are believed to have evolved from these bacterial 
classes via degenerative evolution. Their uniqueness is also reflected by their usage of 
UGA codon (normally a stop codon) to encode for tryphophan [4].The small genome 
sizes correspond with their inability to synthesize nutrients and thereby they depend on 
the host for nutrient acquisition and are considered obligate parasites [5].  
Due to their limited biosynthetic capabilities resulting from degenerative evolution, 
most mycoplasmas are parasitic in nature, exhibiting strict host specificities and are 
common pathogens of humans, animals, reptiles, fish, insects, and plants [1]. Primarily 
they are pathogens of respiratory and urogenital tracts, but are also known to cause 
systemic diseases of the eyes, mammary glands and joints [1]. Mycoplasmas are also 
increasingly found in unnatural habitats, for example urogenital mycoplasma M. 
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hominis have been isolated from respiratory tract and joints [1, 6, 7]. However there are 
several commensal mycoplasmas that live innocuously within their host as part of the 
natural flora, without any detrimental effects. Even though very few mycoplasmas are 
associated with mortality, economic significance arises from the extreme morbidity they 
cause in humans, pets, and livestock, especially in poultry.  
1.2 History of mycoplasmas 
   More than a century ago in 1898 a bovine pleuropneumoniae like organism was 
successfully cultivated by Nocard and Roux which set the stage for mycoplasmology, a 
new area in science. Even though these organisms have long been known, their taxonomy 
has been contentious including the simplest classification; bacteria or a virus? In 1930 the 
virus status of mycoplasma was refuted. In 1935 an L-form (a laboratory strain after 
partial or complete removal of cell wall) of Streptobacillus moniliformis was isolated by 
Klienenberger, which significantly resembled mycoplasmas in their colony formation, 
morphology and filterability. The possibility that mycoplasmas represented a stable L 
form of a yet to be identified parent bacteria led to the coining of their independent 
taxonomic status. For almost 30 years it was believed that mycoplasmas are nothing but 
L-form variants of common bacteria until in 1969 the genomic analysis data containing 
the guanine and cytosine content of mycoplasmas became available, and ruled out this 
conception [8]. From an evolutionary perspective, mycoplasmas not only have lost their 
cell wall due to degenerative evolution but also have lost many more genes responsible 
for various functions including biosynthetic capabilities like de novo biosynthesis of 
purines, a functional tri-carboxylic acid cycle, and a cytochrome mediated electron 
transport chain system. This has led to a significantly diminished genome size, 
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differentiating them from the L-forms [4, 9]. Hence, mycoplasmas are now recognized as 
the smallest known self-replicating bacterium. The name ‘mycoplasma’ was derived from 
Greek mykes or fungus and plasma for something molded to denote the fungus like 
morphology of Mycoplasma mycoides the first identified mycoplasma. Current 
classification of mycoplasma was done by Edward and Freundt in 1956 and consists of 
the order Mycoplasmatales, family Mycoplasmatacae, genera Mycoplasma and several 
species [9, 10].  
1.3 Mycoplasmosis in various species 
1.3.1 Mycoplasmosis in humans 
Many different species of mycoplasmas are known to infect humans including 
Mycoplasma pneumoniae, Mycoplasma genitalium, Mycoplasma penetrans, Mycoplasma 
hominis, Mycoplasma salivarium, Mycoplasma fermentans and others. The most well 
studied pathogen among them is M. pneumoniae, known to cause upper and lower 
respiratory disease, tracheobronchitis, pharyngitis and community acquired pneumonia or 
“walking” pneumonia [11]. In children, inflammation of the throat with or without 
cervical adenopathy, conjunctivitis and myringitis are also observed. However, younger 
children are more likely to present with coryza and wheezing, and occasionally progress 
towards pneumonia, but older children and elders are more likely to develop 
bronchopneumonia involving one or more lobes, sometimes leading to hospitalization. 
Mild asymptomatic infections are more frequently observed in adults with very few 
progressing to bronchopneumonia [12]. A significant percentage M. pneumoniae 
infection may lead to extrapulmonary manifestation. Chronic M. pneumoniae infections 
are sometimes associated with asthma and chronic obstructive pulmonary disease likely 
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due to a Th2 skewed host immune response [13, 14]. Central nervous system 
complications including encephalitis, polyradiculitis, cerebellar syndrome, 
encephalomyelitis etc. have also been observed as extrapulmonary manifestations of 
infection. Although rare, cardiovascular, renal and gastrointestinal complications and 
even hemolytic anemia have been found to be associated with M.pneumoniae infection 
[12].  
Mycoplasma genitalium is another fairly well studied human pathogen known to be 
associated with urogenital complications. It is known to cause a sexually transmitted non-
gonococcal urethritis in men and pelvic inflammatory disease in women [15-17]. 
Mycoplasma penetrans, the first identified invasive mycoplasma has been observed to 
penetrate eukaryotic cells using their tip structure and is also known to colonize human 
urogenital tract and have been associated with HIV suggesting a possible co-infection[17-
19]. Mycoplasma hominis is another known urogenital pathogen associated with bacterial 
vaginosis and preterm births [17, 20] 
1.3.2 Mycoplasmosis in animals 
Mycoplasma mycoides subsp mycoides small colony type (MMMSC) and 
Mycoplasma bovis are two well-known pathogens in bovines. MMMSC is highly 
contagious and cause bovine pleuoropneumoniae that can sometimes be fatal [21]. M. 
bovis is associated with mastitis and pneumonia in dairy cattle [22, 23]. Mycoplasma 
capricolum subsp. caripneumoniae (MCC) causes caprine pleuropneumonia and are often 
associated with mortality in goats. Mycoplasma mycoides subsp. mycoides large colony 
type and Mycoplasma mycoides subsp. capri can cause mastitis and arthritis in goats [24]. 
Mycoplasma agalactiae is also a well-known caprine mycoplasma that causes mastitis 
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associated reduced milk production [25]. Mycoplasma hyopneumoniae causes highly 
infectious porcine enzootic pneumonia in swine resulting in significant economic losses 
[26]. Mycoplasma hyorhinis can also occasionally cause serofibrinous to fibrinopurulent 
polyserositis and arthritis in pigs [27]. Mycoplasma felis causes conjunctivitis and 
pneumonia in felines as well as pleuritis in equines [28-30]. Mycoplasma pulmonis is a 
rodent respiratory pathogen that resembles atypical pneumonia caused by M.pneumoniae 
in humans and frequently serves as an animal model for this disease. Mycoplasma 
arthritidis is commonly found in rats and cause polyarthritis in mice. This mycoplasma 
possesses a superantigen also known as Mycoplasma arthritidis mitogen (MAM), a 
distinctive feature among all mycoplasmas which is known to polyclonally activate 
lymphocytes and leads to arthritic disease [31].  
1.3.3 Mycoplasmosis in fishes and reptiles 
Mycoplasma crocodyli and Mycoplasma alligatoris are two reptilian mycoplasmas 
[32]. Mycoplasma alligatoris causes lethal invasive disease in alligators including 
necrotizing pneumonia, fibrinous polyserositis, polyarthritis, severe pericarditis, 
necrotizing myocarditis, pyogranulomatous meningitis, and necrotizing synovitis. They 
can rapidly disseminate into various tissues by degrading extracellular matrix proteins 
and can cause acute brainstem hemorrhage. They are called flesh-eating mycoplasma and 
are often associated with mortality [32-34]. Mycoplasma agassizii causes rhinitis, 
palpebral edema as well as nasal and ocular discharge in desert tortoise thereby affecting 
the animal’s ability to breathe and making it difficult for them to survive in the wild. In 
fish Mycoplasma mobile cause severe necrosis of epithelial and gill arches. Name of this 
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mycoplasma was coined due to their fastest gliding motility, a process of binding and 
movement on glass surfaces utilizing a polarized tip structure [35].  
1.3.4 Avian mycoplasmosis 
The first identified avian mycoplasma was Mycoplasma synoviae. It causes infectious 
synovitis in poultry and produces respiratory lesions and airsacculitis [36]. Mycoplasma 
iowae infection is also characterized by airsacculitis, embryo mortality, 
chondrodystrophy, poor feathering etc. in chicken and turkeys [36]. Mycoplasma 
meleagridis cause respiratory illness in poultry [37]. Mycoplasma gallisepticum is the 
most studied of the avian mycoplasmas and is a well-known respiratory and reproductive 
tract pathogen of poultry resulting in significant economic losses to the poultry industry. 
M. gallisepticum cause tracheitis, airsacculitis, respiratory rales, coughing, nasal 
discharge and chronic respiratory disease in chickens especially in the presence of a co-
infection [38-40]. It recently has become a major threat to passerine birds and has been 
isolated from American goldfinches, house finches and purple finches [41, 42]. It causes 
severe periorbital swelling and conjunctivitis with mucopurulent drainage and nasal 
exudate in house finches [43] resulting in drastic decline in house finch population. 
1.4 Mycoplasma host interaction  
   Despite their extremely small genome and lack of various metabolic pathways, 
mycoplasmas are able to evade host immune responses and establish chronic infections 
within wide array of hosts. However mycoplasma host interaction is a quite complex 
phenomenon and various strategies employed by mycoplasma in disease pathogenesis 
and host immune/inflammatory response to infections are discussed in subsequent 
sections.  
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1.4.1 Cytadhesion and gliding motility 
   Mycoplasmas are generally flask shaped with a narrowed tip structure that enables 
gliding motility and mediates tight attachment to host cell surface. Cytadhesion to host 
cells is a necessary step towards disease pathogenesis as mutants lacking cytadhesion are 
avirulent [44, 45]. Their tapered polarized structure of the “tip organelle” is composed of 
an electron dense core containing adhesion molecules and is well-studied in M. 
pneumoniae. In M. pneumoniae, protein P1 is densely aggregated near the tip structure 
along with an associated molecule P30, and mutants lacking P1 or P30 are associated 
with reduced cell attachment and virulence in vivo [46, 47]. Whereas P1 the primary 
adhesion molecule, P30 enables P1 to function properly. The P1 gene has highest G+C 
content in the entire genome and may suggest an unknown exogenous origin [45]. P30 
plays a role in cell development as M.pneumoniae lacking P30 tend to have 
morphological abnormalities [46]. Importantly, P30 is known to possess amino acid 
sequence homology with eukaryotic structural proteins including cross-reactive epitopes 
shared with fibrinogen, keratin, and myosin, and may be implicated as a basis for 
molecular mimicry and post infectious autoimmunity[46, 48]. Both P1 and P30 are 
known to elicit strong immunological responses in convalescent phase sera [46]. Two 
other proteins closely associated with P1 are found in the tip organelle and named P40 
and P90 based on their molecular weight. These are found to be surface localized near the 
tip organelle but not directly associated with receptor binding and may aid in cytoskeletal 
organization or clustering of P1 at the tip [46, 47]. Other groups of proteins called 
HMW1-3 (high molecular weight protein) also help anchor P1 at the tip organelle [49, 
50]. These accessory molecules are known to maintain proper distribution of the adhesins 
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and loss of these proteins lead to loss of attachment capabilities suggesting their 
significant role in cytadherence. Other proteins including P65 and P200 share similar 
structural features as HMW1 and HMW3 and probably play important role in M. 
pneumoniae cytoskeletal organization. HMW2 may also play an important role as 
mycoplasma cytoskeletal protein due to the similarity in conformation with the 
filamentous portion of myosin heavy chain [45, 47, 51, 52].  
Like M. pneumoniae P1, M. genitalium and M. gallisepticum contain homologous 
cytadhesion molecules named MgPa and GapA. Other mycoplasmas like M. hominis, M. 
hyopneumoniae, M. mobile and M. agalactiae also possess cytadhesion molecules [44, 
53-56], although apparently not homologous to M.pneumoniae P1 based on sequence 
comparisons. In M. gallisepticum, analysis of the GapA operon revealed the presence of 
another gene, termed crmA, with sequence homology to P40 and P90 of M. pneumonia 
[53]. Loss of CrmA also reduced virulence and cytadhesion capabilities of M. 
gallisepticum suggesting its association with GapA for cytadhesion [57]. M. hominis 
cytadhesin OppA seems to have an ecto ATPase activity that helps in cytadhesion [54]. 
Very recently it was identified that cytadherence is not only necessary for attachment to 
host cell surface but are also involved in initiation of host inflammatory response via 
ligation to TLR-4 [58, 59].  
Gliding motility is yet another unique phenomenon observed in mycoplasma and 
involves the polarized tip structure, which enables them to bind and move on solid 
surfaces. Although not all pathogenic mycoplasmas possess gliding motility, some 
mycoplasma species do including M. mobile, the fastest mycoplasma, M. gallisepticum 
and M. pneumonia. Energy required for this process is generally obtained via ATP 
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hydrolysis [60, 61] In M. gallisepticum cytadhesion proteins GapA and CrmA were found 
to be associated with gliding motility as mycoplasmas lacking these genes are unable to 
move on solid surfaces [62, 63]. Gliding motility allows mycoplasmas to escape 
mucocilary clearance, enabling them access the mucosal epithelial cells. Therefore these 
properties across various species of mycoplasma play a significant role in virulence and 
disease pathogenesis upon infection.  
1.4.2 Invasion of Host cells 
Mycoplasmas are generally known as extracellular pathogens by virtue of colonizing 
the mucosal surfaces, however more recent research has identified their capability for 
invasion and survival within non phagocytic host cells, aiding in evasion of host immune 
response[19, 64-70]. Initailly only M. penetrans was thought to be able to invade host 
cells, but more recent studies identified M. gallisepticum, M. synoviae, M. suis, M. 
fermentans, M. hyorhinis, M. bovis among others to have invasive capabilities[67, 68, 71-
78]. Most of these pathogens were found to invade and reside within non-phagocytic 
cells. M. gallisepticum was found to invade chicken erythrocytes, fibroblasts and HeLa 
cells, with a low passage virulent strain being significantly more efficient in invasion in 
vitro and systemic spread in vivo than a high passage cytadherence deficient avirulent 
strain [67, 68, 71, 76]. A recent report demonstrated that the ability of M. gallisepticum to 
invade host cells depends on host cell extracellular matrix (ECM) molecules like collagen 
type IV, plasminogen and fibronectin [77-81]. However, there is no clear evidence that 
the organism can invade tracheal epithelial cells, as they were predominantly found to 
colonize the mucosal surface and were only rarely found inside phagocytic vacuoles ([82] 
and unpublished observations, see appendix).  
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1.4.3 Host Cell Receptors 
Host cell surface sialoglycoconjugate receptors are well established for their role in 
mycoplasma attachment [44]. M. pneumoniae is also known to attach to human 
erythrocytes via a carbohydrate moiety on an active glycoprotein and a sialic acid free 
glycoprotein receptor on human lung MRC-5 cells [83-85]. In very recent literature it has 
been referred that cytadhesion of M.pneumoniae occurs via TLR-4 receptors present on 
host cell [59] whereas it has long been known that mycoplasmal lipoproteins are able to 
precipitate host innate immune responses via ligation of membrane lipoprotein to host 
TLR-2 homodimers, or TLR1/2 and TLR2/6 heterodimers [86].  
Mycoplasmas are known to bind cilia present on the respiratory epithelial cell surface 
as has been shown with Mycoplasma hyopneumoniae and their binding to porcine ciliated 
respiratory epithelial cells. Zhang et al 1994 reported M. hyopneumoniae specifically 
bind to glycolipid receptors on cilia and suggested these to be the major receptors for 
mycoplasma to cytadhere ciliated cells [87]. Several proteins from M. hyopneumoniae 
were found to be associated with cilium binding including P97 adhesin, protein P159 and 
two surface proteins MHP385 and MHP384 [88-90]. A very recent study reported that M. 
pneumoniae colonization of human respiratory epithelial cell requires cilia as a conduit 
for mycoplasma to access the host cell surface [91]. It is long been known that 
mucociliary apparatus impairs bacterial colonization on host epithelial cell surface, but 
mycoplasmas are able to induce ciliostasis which help them avoid mucociliary clearance 
[92, 93]. During mycoplasma infection squamous metaplasia, a non-cancerous change in 
the surface lining of ciliated columnar epithelial cells to a squamous morphology is 
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observed along with loss of cilia. It is believed that both these changes function as a host 
defense mechanism to avoid mycoplasma attachment on epithelial cell surface [93, 94] 
The above discussed ciliary functions are attributed to the motile cilia that helps in 
clearance of pathogens, whereas non-motile or primary cilia are known to induce 
intracellular signaling. This signaling often occur in presence of cytokine like IL-1 and 
leads to production of other cytokines, nitric oxide and prostaglandin E2 that in turn help 
in clearance of pathogens. However, involvement of primary cilia during mycoplasma 
infections remains unknown [95].  
1.4.4 Mycoplasma lipoproteins  
Mycoplasmas do not possess cell walls or outer membranes, and thus lack 
lipopolysaccharide (LPS), a known endotoxin, as well as other cell wall components like 
lipotechoic acid, flagella, and peptidoglycan. These cell surface molecules, also known as 
pathogen associated molecular patterns (PAMP), ligate to specific host cell receptors of 
the innate immune system known as pattern recognition receptors (PRRs) like Toll like 
receptors (TLRs) or NOD like receptors (NLRs) among others [96, 97]. TLRs are the 
most common PRRs to ligate PAMPs and precipitate an inflammatory response [97, 98], 
for example bacterial lipopolysaccharides ligate to host TLR-4 and flagellin ligate to 
TLR-5.  
Mycoplasma membranes are composed of a single lipid bi-layer with numerous 
embedded integral and peripheral proteins and membrane anchored lipoproteins [99-101]. 
Due to the lack of cell wall and outer membranes, mycoplasma lipoproteins are the only 
PAMP available on mycoplasma cell surface, and are very well known for their 
inflammatory properties and capability of mounting innate immune responses [102]. A 
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significant percentage of mycoplasma genomes are dedicated to these lipoproteins; for 
example in M. gallisepticum, VlhA (variable lipoprotein hemagglutinins) encoding genes 
occupy 10.4% of the total genome [103] suggesting the significance of mycoplasmal 
lipoproteins for bacterial fitness. Mycoplasmas are also capable of phase variable 
expression of their surface lipoproteins, aiding in circumvention of host immune 
responses. The first mycoplasma lipoproteins found to interact with a host TLR was 
macrophage activating lipopeptide-2 (MALP-2) of M. fermentans and a 44 kDa 
lipoprotein from M. salivarium. TLR-2 but not TLR-4 knockout mice remained 
unstimulated by MALP-2, suggesting that MALP-2 binds to TLR-2 and initiates the 
inflammatory response [104-107]. Later interaction of mycoplasmas with host TLRs 
identified ligation of TLR-1/2 heterodimers with tri-acylated lipoproteins and TLR-2/6 
heterodimers with di-acylated lipoproteins, sometimes requiring involvement of CD-14. 
This led to subsequent activation of NF-κB in a MyD88 dependent pathway [86, 100, 
107-112]. It was also observed that an R-stereoisomer of MALP-2 was about a 100 times 
more potent in leukocyte cytokine production than an S- stereoisomer [113]. Several 
studies that reported inflammatory activities of mycoplasma lipoproteins also identified 
that the N-terminal lipid moiety rather than the protein moiety was responsible for 
activation of NF-κB and pro-inflammatory cytokine secretion [86, 100, 105, 107-112]. 
These reports suggest immense importance of structure and conformation in 
inflammatory properties of mycoplasma lipoproteins. The NF-κB activation after TLR 
ligation mediated by mycoplasma lipoproteins was found to induce several chemokines 
and cytokines including TNF-α, IL-6, MIP-1β [86, 100, 107-112, 114]. These genes were 
also expressed during M. gallisepticum infection, however it is not known if induction of 
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these genes is mediated by M. gallisepticum lipoproteins. A MALP-2 homolog in M. 
gallisepticum has been characterized and was found to have no effect on attachment, 
growth or virulence of the organism, but potential role of P47 in induction of cytokines is 
yet to be elucidated [115, 116]. A truncated form of M. synoviae lipoprotein MSPB was 
also found to induce nitric oxide and cytokine expression in chicken monocyte derived 
macrophages via ligation of TLR-15 [117, 118]. Mycoplasma lipoproteins were not only 
found to be active in vitro, but several in-vivo studies also reported their role in 
inflammation [106, 119, 120] . MALP-2 was found to induce MIP-1α, MCP-1, and MIP-
2, thereby promoting leukocyte infiltration in mouse peritoneal cavity after peritoneal 
injection [106]. TLR-2 was found to play a role in innate resistance against M.pulmonis 
infection [121].  
TLR ligation by lipoproteins was also found to be responsible for leukocytic cell 
death both via apoptosis and necrosis. Lipoproteins from M. salivarium and M. 
fermentans were found to preferentially induce necrotic cell death in lymphocytic cell 
lines MOLT-4 and Raji and one monocytic cell line THP-1 ,whereas induced apoptotic 
cell death in another monocytic cell line (HL-60) and was dependent on both caspase 
activation and TLR-2 ligation [122, 123]. Later MALP-2 was found to induce a 
sequential bifurcate response in HEK-293 cell line via ligation to TLR-2/6 heterodimer. 
This lead to NF-κB activation and pro-inflammatory cytokine production as an early 
event, partially mediated by MyD88 and FADD, and at later stages initiated 
apoptosis regulated by p38 MAPK , MyD88 and FADD [124]. Similar observations were 
also made with M. genitalium lipoproteins that induced pro-inflammatory cytokine 
secretion as well as apoptosis by activating NF-κB in THP-1 cells. M. penetrans 
15 
 
lipoproteins also induced apoptosis in a similar fashion in mouse macrophages [125, 
126]. Surprisingly, a study by Gerlic et al. reported that M. fermentans lipoproteins in 
fact inhibit TNF-α induced apoptosis in U937 cells [127] and implied that cell lines used 
by Into et al. are uncharacteristically responsive to TLR induced apoptosis, resulting in a 
skewed dataset. Another study by Hopfe et al. reported that M. hominis ecto-ATPase 
OppA induced ATP release and apoptotic cell death of HeLa cells [128], and Into et al. 
also showed that mycoplasma lipoproteins induce ATP release from cells, which in turn 
binds to the purinergic receptors and mediate cell cytotoxicity [122].This suggests that 
TLR mediated NF-kB activation may not be the only pathway involved in the induction 
of apoptosis. Unpublished data from our lab also found apoptosis to be an important 
factor during M. gallisepticum infection of chickens, identified by tunnel assay and pro-
apoptotic cytokine gene expression but it is not known if apoptosis were mediated by 
lipoproteins. 
1.5 Modulation of Host Immune System and Immune Response  
The initial interaction of mycoplasmas with their host occurs at mucosal surfaces and 
subsequently leads to a cascade of inflammatory events. This phenomenon is an 
important aspect of disease pathogenesis and often determines the susceptibility or 
resistance to the disease. Whereas innate immune responses are critical in early response 
and control of infection, adaptive immune responses have contrasting roles in control and 
pathogenesis of the infection. However many mycoplasma diseases lead to persistence of 
organism and ineffective immune responses against the infection leads to development of 
chronic inflammation. Interaction between mycoplasma and host immune system is a 
complex phenomenon, and various aspects of this interaction has been described below 
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1.5.1 Innate response to mycoplasma infection  
The innate response to infectious agents involves cells of the innate immune system 
like polymorphonuclear leukocytes (PMN), macrophages, NK cells that are able to 
mediate direct killing via phagocytosis or by releasing antimicrobial peptides like 
defensins, collectins, complement, lysozyme, reactive oxygen or and/or nitrogen among 
others. Mycoplasmas are capable of inducing ciliostasis and possess gliding motility 
thereby escaping clearance by mucocilary action and facilitating adhesion to the 
respiratory epithelial cells [93, 129]. Mycoplasma host interaction occurs not only by 
cytadhesion but also by ligation of mycoplasma surface exposed lipoproteins to host toll 
like receptors (TLRs) leading to activation of NF-κB and downstream production of 
cytokine and chemokines [1, 59, 86, 100, 102, 108, 120, 130-132].  
Danger associated molecular patterns or DAMPs are also known to induce 
inflammatory responses and involve nuclear or cytosolic proteins and ATP. DAMPs are 
recognized via intracellular NOD (nucleotide binding oligomerization domain) receptors 
and mediate activation of inflammasomes and subsequent induction of inflammatory 
responses. Mycoplasma infection often leads to extracellular release of ATP and 
activation of inflammasomes via ligation of ATP to P2X7 receptors and subsequent 
release of IL-1β, thereby contributing to the inflammatory response [58, 133, 134]. 
Extracellular ATP is also known to enhance macrophage activation and in certain cases 
apoptosis, mediated by mycoplasmal lipopeptides [122, 135]. Besides release of ATP 
from cells, mycoplasmas were also found to activate NLRP3 inflammasome promoting 
migration and invasion of gastric cancer cells [136].  
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Most studies that examine the interaction of host innate immune system with 
mycoplasmas utilized Mycoplasma pulmonis, a rodent respiratory pathogen. Alveolar 
macrophages (AMs), were found to be of major importance in antimycoplasmal defense 
during this infection and directly correlated with increasing numbers of AMs. Those 
mycoplasma strains that were able to evade phagocytosis by AMs were more successful 
in survival within the host and frequently resulted in exacerbated disease in comparison 
with strains which were easily phagocytized [132, 137]. Mycoplasmas on the other hand 
were found to be phagocytized by polymorphonuclear leukocytes (PMN) without 
antibody mediated opsonization and are presumed to be either receptor or complement 
mediated. Phagocytosis without opsonization is often a critical step for intracellular 
survival; therefore PMNs presumably play no role in anti-mycoplasma defense and in 
fact, may contribute to dissemination of mycoplasma to other organs [138, 139].  
Mycoplasmas are known to resist phagocytosis in absence of opsonins and since M. 
pulmonis is trypsin sensitive, presence of an antiphagocytic protein on their surface is 
possible. Nonspecific opsonins are suggested to play an important role in 
mycoplasmacidal activity and might involve complement breakdown product, fibronectin 
and C-reactive protein. Complement proteins alone were found to be ineffective in 
mycoplasma killing, and the ability to avoid killing by the complement activation 
pathway could be a possible virulence mechanism of mycoplasmas [140, 141].  
Surfactant proteins were also found to play an important role in mycoplasma 
clearance. SP-A specifically interacts with alveolar macrophages via SP-A receptor and 
was shown to affect release of reactive oxygen species, chemotaxis of 
monocytes/macrophages as well as enhancing their phagocytic capabilities. Reactive 
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oxygen and nitrogen species including peroxynitrite and nitric oxide generated by 
macrophages were also implicated in oxidative killing of mycoplasmas [132]. However 
mycoplasmas were found to be resistant to oxidative attack by inhibiting production of 
reactive oxygen-nitrogen species via catalase utilization and argininine depletion, thereby 
evading oxidative killing during phagocytosis [132, 142-145].  
Several studies have identified enhancement in NK cell activity induced by various 
mycoplasma species [132]. MAM was found to augment lytic capability of human NK 
cells directly or via indirect effect of cytokines produced from T cells [146]. It was also 
found that intraperitoneal injection of Mycoplasma pulmonis increased splenic and 
pulmonary NK cell activity and NK cell depletion resulted in decreased killing of this 
pathogen and disease exacerbation [132, 147]. 
1.5.2 Adaptive response to mycoplasma infection 
The adaptive immune response is a highly specialized mechanism involving 
lymphocytes (B and T cells), antigen presenting cells (dendritic cells, macrophages etc.) 
and various processes to eliminate specific microorganisms. Adaptive immune responses 
are generally induced within a few days after initial exposure to pathogenic microbes 
and create immunological memory leading to enhanced responses upon subsequent 
encounters. Adaptive immune responses probably have the most significant effect on 
mycoplasma disease progression. However, whereas some adaptive responses play 
beneficial role in controlling the disease, while other elements may lead to severe 
immunopathology as a result of immune dysregulation. 
Mycoplasma infections are generally associated with infiltration of PMNs, 
macrophages, B and T cells in the submucosa. However, the precise role of B and T 
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cells during mycoplasma infections, bacterial clearance, restoration of tissue 
morphology and chronicity of infection are poorly described. In any case, lymphocyte 
recruitment and activation play an important role in mycoplasma pathogenesis. M. 
pneumoniae infection causes acute peribronchial and perivascular lymphoid 
accumulation and destruction of respiratory epithelium. Increase in pulmonary T cells 
has also been observed during M. pulmonis infection and both B and T cell accumulation 
in lungs of goats are observed upon mycoplasma infection [148-150]. However 
lymphocyte infiltration appears to contribute to both immunopathogenesis and control of 
disease. For example, nude or SCID mice develop significantly less severe lung disease 
than wild type mice following M. pulmonis infection, but these mice are also susceptible 
to a more widely disseminated systemic disease [151-153]. Reconstitution of SCID mice 
with lymphocytes led to development of as severe lesions as normal mice and 
reconstitution with T cells alone promotes development of more severe lesions. But 
surprisingly these results have little to no effect on number of mycoplasmas in the lungs, 
suggesting T cells may not play a role in localized resistance [151, 153]. Cell-mediated 
immunity was also found to be of limited importance during M. pneumonia infection, as 
severity of pneumonia did not increase with T-cell deficiencies in human subjects [151, 
154]. T helper cells are known to contribute to inflammatory responses after 
mycoplasma infection. During M. pneumoniae, M. agalactiae, M. pulmonis and M. bovis 
infection T cells were found to be the major cell type associated with the disease and 
CD4+ T helper cells were more predominant than CD8+ T cells [150, 153]. However 
CD8+ T cells are found to play important role during M. gallisepticum, M. pneumoniae, 
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M. agalactiae, M. pulmonis and M. bovis infection albeit at smaller numbers [39, 150, 
153, 155, 156].  
Antibody responses also seem to be important in prevention of mycoplasma 
dissemination to extra pulmonary tissues [151]. Infection with various species of 
mycoplasmas were found to elicit responses from all type of antibody classes including 
IgA, IgM, IgD, IgE and IgG. IgM is often the first antibody generated upon mycoplasma 
infections and later a switch to other classes of antibodies are observed based on the 
activity of T helper cells and cytokines [153]. IgG response predominate after initial 
IgM production and is the major antibody class involved in control of mycoplasma 
infections. IgG can mediate complement activation, and opsonization of mycoplasmas 
by phagocytes and various subclasses of IgG (and Fc receptors) determine cell types that 
phagocytize the pathogen [157]. For example IgG1 mediates killing of M. bovis via 
macrophages and IgG2 via both macrophages and neutrophils [153]. It is also known 
that maternal IgG can provide protective immunity from mother to fetus or newborn via 
passive transfer through placenta [153]. IgD responses were also elicited upon M. 
penumoniae infection however the role of IgD in not well understood [153, 158].  
Consistent with mycoplasmas being predominantly mucosal pathogens, antibody 
responses at mucosal sites are primarily dominated by IgA and IgE antibody isotypes. 
Mycoplasma specific IgA was found in response to both genital and respiratory tract 
infections [159-162]. Resistance to M. pneumoniae infection in fact correlates better 
with a mucosal IgA response compared to serum IgG or IgM response [153]. IgE has 
also been found during respiratory mycoplasmosis and as IgE is associated with allergic 
response, it is believed that a M. pneumoniae mediated IgE response leads to 
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exacerbation of asthma [163, 164]. However a recent study identified association of anti 
M. pneumoniae IgM, but not IgG or IgE in asthmatic children [165]. Therefore it seems 
from majority of studies that local antibody production may be more important than 
circulating antibodies in control of mycoplasmas.  
Taken together, it is safe to say that mycoplasmas are able to precipitate both innate 
and adaptive components of the host immune responses. Whereas macrophages are 
significant components aiding in phagocytosis and clearance of mycoplasma, PMNs may 
in fact aid in dissemination of mycoplasmas to other tissues [138]. Both B and T cells 
play critical roles in clearance and prevention of dissemination of mycoplasma but may 
also contribute to the significant immunopathology associated with the disease. Hence 
induction of innate and adaptive immune response to mycoplasma whereas beneficial, 
promotes lesion severity and can be considered a double-edged sword. Therefore, 
induction of local neutralizing antibodies without promoting severe immuno-pathology is 
to be considered during production of mycoplasma vaccines.  
1.5.3 Role of chemokines and cytokines during mycoplasma infection 
Chemokines and cytokines also play a major contributory role in manifestation of 
disease during mycoplasma infection. During epithelial colonization of mucosal 
pathogens, chemokines and cytokines produced by airway epithelial cells are known to 
recruit leukocytes to the submucosa [166]. Even though there is scarcity of data on 
response of epithelial cells to mycoplasma infections, a handful of studies support the 
notion that these molecules play an important role in the host response, both protective 
and maladaptive. During Mycoplasma genitalium infection, human cultured endocervical 
epithelial cells were found to produce IL-6, IL-7, IL-8, MCP-1, GM-CSF during acute 
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stages of infection while IL-8, MIP-1β and MCP-1 predominated during chronic stages of 
infection [112, 167, 168]. M. pneumoniae infection triggered the release of IL-8 and 
RANTES from human nasal epithelial cells and expression of IL-1β, IL-8 and TNF-α 
from A549 cells [169]. These chemokines and cytokines are well known for their role in 
recruitment and activation of leukocytes and therefore may play a significant role in the 
immunopathology observed during mycoplasma infection. 
  Macrophages and monocytes have also been found to produce TNF-α, IL-1β, and 
MIP-1β upon infection to live mycoplasma or mycoplasma lipid associated membrane 
proteins (LAMPs) [86, 100, 108, 120, 170, 171]. Cytokines produced by lymphocytes are 
often major factors in determining the outcome of immune responses and the complex 
interplay between cells and cytokines often determine disease outcomes. Various studies 
on mycoplasmas identified differential cytokine patterns during the acute and chronic 
stages of the disease. The presence of IL-4, IL-5, IL-6, IFN-γ, TNF-α and several other 
cytokines was found to correspond with the presence of gross inflammatory lesions [153, 
172, 173]. Increased levels of IL-4 in broncho-alveolar lavage fluid was found in patients 
with M. pneumoniae infection suggesting a Th2 type response [174]. However a recent 
study implicated vaccine-mediated exacerbation of disease upon M. pneumoniae 
infection that was associated with increased IL-17 level and corresponding eosinophilia 
[175] and mycoplasma specific IFN-γ production by lymphocytes were observed in M. 
pneumoniae patients. M. pulmonis infected mice were also found to generate both Th1 
and Th2 type cytokine response in lung by day 14 which included IFN-γ, IL-2 as well as 
IL-4, IL-6 and IL-13 [156]. Mycoplasma infections have been shown to mediate a shift 
from Th2 to a mixed Th1/Th2 response [153]. Even though a Th1 response is associated 
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with the exacerbation of disease, cytokines like IFN-γ can activate macrophages, 
allowing them to kill mycoplasmas but generation of a Th2 response may dampen 
macrophage function and promote development of chronic inflammatory disease [143]. 
Therefore the balance between Th1 and Th2 cytokine responses may ultimately 
determine the fate of the disease.  
Often a pro-inflammatory cytokine response can have a concomitant anti-
inflammatory response as has been observed during mycoplasma infections. M. 
hyopneumoniae infection lead to a significant increase in IL-10 production in broncho-
alveolar lavage fluids and IL-10 mRNA levels were found to increase in M. gallisepticum 
and murine mycoplasma diseases [176, 177]. Thus it remains unknown which cytokines 
are protective and which promote disease; hence, further studies are required to fully 
elucidate the chemokine and cytokine responses and identify their specific role during 
mycoplasma infections.  
1.5.4 Non-specific stimulation of immune cells by mycoplasma 
 Several mycoplasma species including M. fermentans, M. pneumoniae, M. hyorhinis, 
M. argini, M. penetrans and M. pulmonis have been found to non-specifically stimulate 
B and T cells [178, 179]. Most of these early studies showed lymphocyte activating 
capabilities of mycoplasmas, without involvement of any accessory cells [179]. MAM 
or M. arthritidis mitogen triggers proliferation of T-cell clones and induces cytotoxic T 
cell development as well as non-specifically stimulates B cells. However unlike other 
mitogens, stimulation through MAM requires antigen presentation by MHC-II bearing 
cells but does not require processing of the antigen [1, 180]. M. fermentans also 
possesses mitogenic potential to human B lymphocytes and was found to polyclonally 
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activate B cells leading to proliferation and subsequent differentiation into plasma cells 
producing non-specific antibodies [178, 181, 182]. Polyclonal activation of B cells by 
mycoplasmas also has been observed in vivo. However characterization of the M. 
fermentans B-cell mitogen only led to partial success and was identified as a membrane 
protein [178]. In addition to mitogenic potential of various mycoplasmas, membrane 
protein preparations of M. pulmonis were also able to chemoattract resting B cells in 
vitro [183]. Taken together it is assumed that mycoplasmas possess significant 
mitogenic activities on host lymphocytes may exacerbate disease severity.  
1.5.5 Surface variable expression of mycoplasma lipoproteins and immune 
evasion 
There are several mechanisms by which pathogens evade host innate and adaptive 
immune responses, which play a significant role in disease causation. Some of these 
mechanisms include molecular mimicry including ligand and receptor mimics, 
complement inhibitors and capsules. Pathogens also have the ability to hide from immune 
surveillance by staying latent or hiding in phagosomes and preventing phagolysosome 
fusion. They also possess antigenic hypervariability thereby escaping from antibody and 
T cell recognition. Some pathogens are able to kill immune cells and phagocytes, block 
adaptive immunity and cytokine production, interfere with TLRs and also modulate 
apoptosis and autophagy [184]. Mycoplasmas possess many mechanisms for antigenic 
hypervariability and are capable of surface variable expression of the major antigenic 
proteins which are essentially components of the lipoprotein family. They possess several 
mechanisms that drive the high frequency of surface variation including spontaneous 
mutation by nucleotide insertion or deletion in short repeat sequences, DNA 
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rearrangements and gene conversion or reciprocal recombination. But only the first two 
mechanisms affect the variable expression of surface lipoproteins aiding in immune 
evasion [185-193] 
A genetic system of 3-8 elements in the chromosome encoding surface lipoproteins 
namely Vlps, were first identified in M. hyorhinis. Each of these vlp genes represents one 
transcriptional element containing a poly-A tract in the promoter region between -35 and 
-10 and are only transcribed when the poly-A tract is 17 bp in length. Therefore insertion 
or deletion of single nucleotide can completely abolish their expression making it a very 
simple ON/OFF switch [185, 192, 194, 195]. M. gallisepticum possesses a similar 
mechanism regulating expression of the vlhA gene family. The importance of these 
molecules is reflected by the percentage of their genome devoted to lipoproteins (vlhA, 
103kb or 10.4% of total genome), which includes 38 genes with signature vlhA gene 
features and 5 pseudogenes possessing vlhA sequence homology. Phase variable 
expression of vlhA occurs in the presence of 12 GAA trinucleotide repeats located at the 
5’ end of the promoter upstream of -35 box. [103, 196-200]. Other types of molecular 
switching associated with phase variation exist including a DNA recombination 
mechanism to alternate silent genes behind a functional promoter in M. bovis, M. 
pulmonis and M. agalactiae. A third type of mechanism involves unidirectional or 
reciprocal gene recombination for generating antigenic variation in M. synoviae and M. 
genitalium.  
Although there are a significant number of studies describing mechanisms of phase 
variation in various mycoplasmas, their role in pathogenesis is still poorly understood. 
Different mycoplasmas possess an inherent ability to undergo phase and antigenic 
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variation and it is believed that antigenic variations resulting from phase variations are 
mechanisms of immune evasion helping mycoplasmas to establish chronic infection in 
the host despite the vigorous inflammatory and immune response [56]. Studies report that 
phase variable vlhA expression is observed in M. gallisepticum within a few days of 
infection, possibly due to selective pressure of the adaptive immune system, when the 
dominant vlhA gene is no longer expressed by most of the re-isolates. Over the ensuing 
weeks they express other members of the gene family suggesting a dual phase response 
during infection [56, 199]. Similar observations have also been made in vitro in the 
presence of antibodies to phase variable lipoproteins or sera from infected animals. It has 
been observed that the presence of antibody or antisera inhibits expression of dominant 
Vsp lipoprotein in M. bovis and upon removal of antibody it regains expression of that 
specific lipoprotein. M. gallisepticum was also found to express alternative VlhA variants 
in the presence of specific antibodies [56, 196, 197, 201]. While it is believed that phase 
and antigenic variation is a mechanism of immune evasion, the role of size variation in 
surface lipoproteins of mycoplasmas however is still poorly understood. Size variable 
expression of mycoplasma lipoproteins have been observed in M. hyorhinis as it is able to 
increase the length of Vlp antigens, which helps in protection from host serum antibodies. 
Nevertheless these sophisticated mechanisms of phase and antigenic variation and 
devotion of a significant proportion of their genome to these mechanisms indicate that 
adaptation to host immune responses is a priority for all pathogenic mycoplasmas.  
1.5.6 Vaccination against mycoplasma diseases 
Mycoplasma diseases are often associated with significant morbidity and sometimes 
mortality in animals and humans. They can cause respiratory and reproductive diseases in 
27 
 
hosts as well as conjunctivitis and arthritis depending on the species of mycoplasma. 
Despite the seriousness of the diseases, very few safe and effective vaccines have been 
developed to combat these pathogens. Most mycoplasma vaccines are either bacterins (a 
suspension of killed mycoplasma) or live attenuated strains. Some of these vaccines are 
mildly virulent providing only partial or transient immunity and are often associated with 
morbidity and may even revert to a virulent phenotype. Some vaccines may even lead to 
exacerbation of disease upon challenge or exposure to virulent strains due to their 
immuno-pathological nature [175, 202]. Therefore, due to these challenges and 
ineffectiveness of antibiotics in controlling mycoplasma infections, the need for safe and 
effective vaccines is urgently required.  
One of the first mycoplasma vaccines developed was for Mycoplasma mycoides 
subsp. mycoides small colony type (MmmSC), the first identified mycoplasma. In fact 
preventive inoculations with inactivated organisms were given even before the organism 
was identified. Later a partially attenuated CBPP (contagious bovine pleuropneumonia) 
vaccine T1/44 was created by 44 serial passages in eggs and has been used for last 60 
years. However, T1/44 only provides short-term immunity and causes adverse effects in 
cattle. CBPP outbreaks were also observed in closed vaccinated herds suggesting that 
T1/44 vaccine retained virulence [203]. Two other vaccines were also created, one a 
recombinant subunit vaccine using immunogenic lipoprotein LppQ [204], which did not 
show protective efficacy despite of two vaccinations at an interval of 6 weeks, but 
exacerbated the disease. Another subunit vaccine was created based on MmmSC capsular 
polysachharide. Antibody response was generated when this vaccine was conjugated with 
ovalbumin, but did not show significant reduction in mycoplasmaemia in blood 
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suggesting inefficient protection [202, 205]. A quadrivalent vaccine for Mycoplasma 
bovis along with respiratory syncytial virus, parainfluenza type 3 and Mycoplasma dispar 
was developed 20 years ago, and showed some protection. Another divalent vaccine for 
M. bovis with Mannheimia hemolytica was also found to be partially protective. More 
recently generated inactivated vaccine containing saponin killed cells was found to be 
more safe and effective against M. bovis [157, 202, 206].  
Mycoplasma agalactiae, Mycoplasma capricolum subsp capricolum (Mcc) and 
Mycoplasma mycoides subsp mycoides large colony type (MmmLC) are pathogens of 
sheeps and goats. Live attenuated vaccines (LAV) were generated for M. agalactiae and 
MmmLC and have been used in Turkey however are known to cause transient infection 
and shedding of mycoplasmas. In Europe, inactivated laboratory strains with added 
adjuvants were created as a trivalent vaccine for M. agalactiae, MmmLC and MCC, and 
are currently marketed. Other vaccines for these pathogens were also created and some 
has shown partial protective efficacy [202].  
Adjuvanated LAVs to control Mycoplasma hyopneumoniae, has been successful and 
led to significant improvement in porcine health worldwide. A recombinant vaccine using 
fusion protein of M. hyopneumoniae subunit R2 of riboneuclotide reductase NrdF and B-
galactosidase was also proven effective in pigs [207]. DNA vaccines based on heat shock 
protein P42 were able to inhibit growth of M. hyopneumoniae in vitro, and also elicited 
both Th1 and Th2 response in mice. M. hyopneumoniae mucosal vaccines using bacterial 
toxin adjuvants, containing P97 adhesin and E-Coli enterotoxin LTB were also developed 
but their efficacy were not tested in any animal models[207].  
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Vaccines for rodent pathogen Mycoplasma pulmonis that causes respiratory disease in 
mice and rats had also been developed. A plasmid based expression library vaccine and 
DNA vaccine coding two M. pulmonis antigens were proven to be partially successful. 
Also a subunit vaccine and monoclonal antibodies against the same proteins inhibited 
growth of this pathogen and showed protection [202].  
Two significant avian pathogens are Mycoplasma gallisepticum and Mycoplasma 
synoviae. A temperature sensitive mutant (MS-H) of M. synoviae, produced by chemical 
mutagenesis was developed, tested and found to be partially protective. This vaccine is 
currently in use worldwide and its protective efficacy lasts for about 40 weeks [202, 208]. 
The significant economic impact of M. gallisepticum infection in poultry birds led to 
employment of several control measures. Administration of antibiotics and maintaining 
single aged M. gallisepticum free flocks has been used to avoid vertical spread. However 
vaccination is the preferred mean of controlling infections.  
Both killed whole cell and live attenuated vaccines have been developed to control M. 
gallisepicum infection and have been used commercially. M. gallisepticum bacterins with 
oil and aqueous emulsion or adjuvanated with aluminum hydroxide were found to be 
effective in preventing severe inflammatory responses and reductions in egg production, 
however could not could not stop mycoplasma from colonizing the respiratory tract and 
neither conferred complete protection [209] . Later use of bacterins was supplanted by 
more effective LAVs. The three most well-known live attenuated M. gallisepticum are 
the F-strain, ts-11 and 6/85 and are commercially produced. The F strain is a field-isolate 
occurring naturally and ts-11 is a temperature sensitive mutant created by chemical 
mutagenesis. The 6/85 strain is also an attenuated strain, however the nature of 
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attenuation is a trade secret [202, 210, 211]. Vaccination of F strain was shown to be 
effective for inhibiting reduction in egg production, but show low to moderate virulence 
in broiler chickens and turkeys[212-214]. The 6/85 strain is avirulent in both chickens 
and turkeys and shows significant protection [215, 216]. The ts-11 strain that can 
replicate in the upper respiratory tract was found to elicit protective immune responses 
without causing disease [217, 218]. Later a ts-11 mutant containing M. gallisepticum 
cytadhesion protein GapA was created and showed a marked increase in protective 
immunity [219, 220].  
Papazisi et al. also developed another attenuated strain, GT5, which is based on non-
virulent strain Rhigh strain complemented with the primary cytadhesin GapA [221]. This 
strain is also devoid of cytadhesion capabilities but is protective in chickens. It showed 
high serum IgG and comparatively lower mucosal IgA, with a corresponding reduction in 
lesion severity and colonization [221]. Protection involved reduced CD4+ and CD8+ T 
cells and B cells compared to control birds infected with M. gallisepticum strain Rlow 
alone. However higher number of mycoplasma specific IgG and IgA secreting plasma 
cells within the trachea of vaccinated birds by day 4 post inoculation suggest significant 
role of antibodies in protective immunity conferred by this vaccine [162]. Another 
metabolically attenuated vaccine strain Mg-7 was also created in 2006 by Hudson et al 
with a mutation in the di-hydrolipoamide (lpd) gene [222] that also showed protective 
efficacy by inducing high M. gallisepticum specific IgG response and lower lesion scores 
[223].  
Two important human mycoplasmas are Mycoplasma pneumoniae that cause atypical 
pneumonia in children and adolescents, and Mycoplasma genitalium that causes non-
31 
 
gonococcal urethritis in women. Use of inactivated vaccines for M. pneumoniae still 
remains unsuccessful. Some heat killed vaccines showed partial protective immunity 
upon oral inoculation in hamsters, however led to disease exacerbation upon parenteral 
vaccination. Hemolytic attenuated mutants in certain cases showed only 10-50% 
protective efficacies but temperature sensitive mutants retained significant virulence and 
therefore has not been used in humans [202, 224-227]. A recent study that tested a 
cytadhesion deficient mutant of M. pneumoniae identified its capability to exacerbate 
disease upon challenge in mice [175].  
1.6 Mycoplasma gallisepticum  
Mycoplasma gallisepticum is a significant poultry pathogen involved in severe 
economic losses of the poultry industry due to a reduction in egg production, hatchability 
and downgrading of carcasses. Both horizontal and vertical disease transmission leads to 
rapid spreading of this pathogen in flocks. This respiratory and reproductive tract 
pathogen can cause severe chronic respiratory disease (CRD) when present in concert 
with other poultry pathogens including Newcastle disease virus, Infectious bronchitis 
virus and E. coli [38-40]. M. gallisepticum infection in chickens is characterized by 
coughing, nasal discharge, respiratory rales, mucous production leading to blockade of 
tracheal lumen, difficulty breathing and sometimes conjunctivitis [228]. More recently M. 
gallisepticum was found to cause ocular infection in house finches leading to significant 
decline in house finch populations [229, 230].  
1.6.1 Virulence factors and pathogenesis 
The critical event for M. gallisepticum pathogenesis is attachment and 
colonization of host respiratory epithelium [44, 45], leading to further pathological 
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changes in the host [82]. M. gallisepticum attachment is mediated by their primary 
cytadhesion molecule GapA, whereas another molecule CrmA facilitates attachment. The 
primary cytadhesin is an orthologoue of M. pneumonia cytadhesion protein P1, and 
CrmA shows sequence homology with ORF6 of M. pneumoniae [53, 231, 232]. Upon 
attachment they can cause release of mucus from goblet cells leading to obstruction of 
tracheal lumen, and rounding and exfoliation of epithelial cells as well as ciliostasis, 
squamous metaplasia and sometimes lysis of epithelial cells [233, 234]. Although it is 
known that M. gallisepticum can invade a variety of cell types as previously described, 
invasion of the tracheal epithelium is not yet documented. An unpublished observation 
from our laboratory using M. gallisepticum 16S riboprobe, did not identify invading 
mycoplasmas in the tracheal submucosa even at day 4 post infection (unpublished, see 
appendix). Another ultrastructural study of M. gallisepticum infection of chicken trachea, 
also was not able to identify invasive capabilities of this pathogen within epithelial cells 
[235]. Yet they are able to cause severe immunopathology associated with infiltration of 
macrophages, heterophils and lymphocytes.  
Evaluation of in vivo pathogenicity of M. gallisepticum, performed by 
determining severity of tracheal and air sac lesions and feasibility of re-isolation of 
mycoplasma from these organs determined that a low passage strain Rlow was virulent 
whereas other strains like A5969 and Rhigh was avirulent and F and S-6 only cause 
intermediate lesions [53, 236, 237]. Comparative analyses of these strains revealed that 
Rhigh, or the high passage avirulent strain do not possess the cytadhesion genes gapA and 
crmA, as well as fibronectin binding genes hlp3 and plpA and a high affinity transporter 
gene hatA. Not only that, but this strain has 64 other point mutations compared to Rlow 
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[57, 237, 238]. A virulence associated gene mslA was also differentially transcribed in 
Rlow strain at levels 6-fold higher than in F strain. Another gene MGA1107 was also found 
to be associated with virulence [238].  
Variable expression of vlhA’s or variable lipoprotein hemagglutinins in M. 
gallisepticum is known to be associated with evasion and subversion of host immune 
responses. A distinct VlhA antigen is believed to be predominantly expressed in a 
population of bacterial cells. When a host humoral response in mounted against it, 
another bacterial population expression a different VlhA proliferate, thereby evading the 
host immune response and establishing a chronic infection. These VlhA’s are also known 
to be involved in cytadhesion to tracheal explants and RBCs and may help in 
mycoplasma dissemination [238, 239].  
1.6.2 Immune/Inflammatory response 
M. gallisepticum infection is associated with infiltration of heterophils, 
macrophages and lymphocytes to the tracheal submucosa, and involve both innate and 
adaptive responses [39, 162, 234]. Early studies investigating immune response to this 
pathogen identified that bursectomy and thymectomy of chickens significantly increased 
their susceptibility to infection suggesting the important role of B and T cells. The 
importance of adaptive immune response was also evident through successful 
vaccination using LAVs [210, 240]. It was observed that B cells play a more significant 
role in M. gallisepticum infection as maternal antibodies (IgY) were able to interfere 
with day 1 vaccination of chicks, and transfer of M. gallisepticum antisera conferred 
protection against air-sacculitis [241]. Protection was also correlated with local antibody 
response in respiratory tract that inhibited attachment of M. gallisepticum to ex-vivo 
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cultured tracheal rings [242]. Antibody mediated protection in vaccinated chickens were 
also observed in a study previously published from our laboratory. Vaccinated chickens 
were found to have higher serum IgG titers, and significantly higher numbers of M. 
gallisepticum specific IgG- and IgA-secreting plasma cells in the trachea compared to 
unvaccinated chickens [162]. However the cellular nature of the inflammatory responses 
to M. gallisepticum infection in the tracheal mucosa still remains controversial. A study 
published from our laboratory in 2005 reported B cells to be the pre-dominant cell types 
in tracheal submucosa of chicken after M. gallisepticum infection as early as 1 day post 
infection. By day 4, B cells were found to be surrounded by clusters of CD4+ T cells in 
vaccinated chickens and unvaccinated chickens had an increased number of B cells 
clustered or scattered throughout the lamina propria with interspersed CD4+T cells. 
CD8+T cells were also found scattered throughout the lamina propria [162]. Gaunson et 
al. on the other hand, reported initial response dominated by CD8+T cells and gradually 
replaced by CD4+T cells and subsequently predominated by B cells. However their 
experiments were done using a different strain of M. gallisepticum and might explain the 
observed differences [243]. Even though presence of various phenotypes of T 
lymphocytes are known to infiltrate tracheal tissue during M. gallisepticum infection in 
chickens, very little evidence remains on the role of T cells, especially cytotoxic T cells 
[39].  
Chemokines and cytokines have also been found to play a significant role during M. 
gallisepticum infection [115]. Production of pro-inflammatory chemokines and cytokines 
were found to non-specifically stimulate B and T cells [1]. Lam et al showed that in vitro 
infection of monocytes and macrophages caused induction of specific chemokines and 
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chemokines [170]. However, how epithelial cells, the primary site of M. gallisepticum 
attachment, influence the induction of inflammatory responses is not yet known.  
1.7 Specific Aims 
Although several advances have been made in our understanding of mycoplasmal 
disease pathogenesis and host pathogen interactions, the dynamics of the interaction of 
M. gallisepticum with its host remains incomplete. The research described in this 
dissertation aims to characterize the cellular and molecular events of host-pathogen 
interactions during M. gallisepticum disease pathogenesis in more relevant situations. 
The first study was aimed at identifying how M. gallisepticum lipid associated 
membrane proteins or LAMPs interact with chicken tracheal epithelial cells; and how 
these interactions may be important for mycoplasma disease pathogenesis. The 
hypothesis of this study was that M. gallisepticum LAMPs ligate to TLR-2 on chicken 
tracheal epithelial cells and up-regulate inflammatory genes via activation of NF-κB. The 
specific aims for this research study were 
1. To characterize differential gene expression in primary tracheal epithelial cells 
cultured in vitro upon exposure to LAMPs from a virulent (Rlow) and a non-
virulent (Rhigh) M. gallisepticum strain as well as both the live strains using 
microarray and RT-qPCR analysis 
2. To characterize expression of inflammatory genes in chicken tracheal epithelial 
cells upon ex vivo exposure of trachea to LAMPs and live mycoplasma using RT-
qPCR 
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3. To identify if TLR-2 ligation of LAMPs are involved and leads to downstream 
activation of NF-κB to initiate the above mentioned phenomenon from chicken 
tracheal epithelial cells using specific inhibitors.  
 
Whilst the first study was aimed at understanding the role of M. gallisepticum and 
associated LAMP mediated activation of tracheal epithelial cells, what happens next 
remained unknown. Mycoplasma infections as previously described are associated 
with severe leukocyte infiltration into the submucosa and macrophages are one of the 
very important cell type involved in this response. Whereas macrophages play 
significant role in mycoplasma clearance, they are also known for the production of 
cytokines associated with inflammatory lesions, and chemokines and cytokines 
associated with macrophage activation were observed to be differentially regulated in 
chicken trachea upon experimental infection with M. gallispeticum [115, 132, 170, 
172, 173]. Therefore a second study was designed to identify how mycoplasma and 
host epithelial cell interaction might be responsible for the inflammatory responses 
observed during M. gallisepticum infection, in context of macrophages. In this study 
we also tried to identify why a virulent strain of mycoplasma is able to elicit a more 
robust immunopathology when compared to a non-virulent strain. Specific aims of 
this study involved are as follows 
1. Chemotaxis assay for HD-11 cells (chicken macrophage cell line) towards the 
conditioned medium obtained from tracheal epithelial cells exposed to live M. 
gallisepticum strain Rlow or Rhigh. 
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2. Co-culture assay of chicken macrophage cell line HD-11 with tracheal epithelial 
cells exposed to live M. gallisepticum strain Rlow or Rhigh to identify chemokine 
and cytokine gene expression in HD-11 cells in response to epithelial cell derived 
mediators 
3. Chemokine and cytokine profile of HD-11 cells upon exposure to various 
multiplicity of infection of live M. gallisepticum strain Rlow or Rhigh as positive 
controls. 
 
These studies contribute to a body of knowledge regarding the mechanisms by which 
M. gallisepticum, through its interaction with the host respiratory epithelial, influences 
the regulation of inflammatory genes and secondary events including macrophage 
chemotaxis and activation. This work bring us one step closer to understanding how this 
primarily extracellular pathogen mediates an over-exuberant inflammatory response by 
cytadhering to the respiratory epithelium, and how this can be mediated without 
mycoplasmal invasion of the epithelial cells or the underlying tissue. Our results also 
explain why virulent strains are always more efficient at initiating and sustaining 
inflammatory responses and advance our knowledge of how the pathogen manipulates 
host immune responses to establish a chronic infection.   
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2.1 Abstract 
Mycoplasma gallisepticum-mediated respiratory inflammation in chickens is 
associated with accumulation of leukocytes in the tracheal submucosa. However the 
molecular mechanisms underpinning these changes have not been well described. We 
hypothesized that the initial inflammatory events are initiated upon ligation of 
mycoplasma lipid associated membrane proteins (LAMP) to TLRs expressed on chicken 
tracheal epithelial cells (TEC). To test this hypothesis, live bacteria or LAMPs isolated 
from a virulent (Rlow) or a non-virulent (Rhigh) strain were incubated with primary TECs 
or chicken tracheae ex vivo. Microarray analysis identified up-regulation of several 
inflammatory and chemokine genes in TECs as early as 1.5 hours post-exposure. Kinetic 
analysis using RT-qPCR identified the peak of expression for most genes to be at either 
1.5 or 6 hours. Ex-vivo exposure also showed up-regulation of inflammatory genes in 
epithelial cells by 1.5 hours. Among the commonly up-regulated genes were IL-1β, IL-6, 
IL-8, IL-12p40, CCL-20, and NOS-2, all of which are important immune-modulators 
and/or chemo-attractants of leukocytes. While these inflammatory genes were up-
regulated in all four treatment groups, Rlow exposed epithelial cells both in vitro and ex 
vivo showed the most dramatic up-regulation, inducing over 100 unique genes by 5-fold 
or more in TECs. Upon addition of a TLR-2 inhibitor, LAMP-mediated gene expression 
of IL-1β and CCL-20 was reduced by almost 5-fold while expression of IL-12p40, IL-6, 
IL-8 and NOS-2 mRNA was reduced by about 2-3 fold. Conversely, an NF-κB inhibitor 
abrogated the response entirely for all six genes. miRNA-146a, a negative regulator of 
TLR-2 signaling, was up-regulated in TECs in response to either Rlow or Rhigh exposure. 
Taken together we conclude that LAMPs isolated from both Rhigh and Rlow induced rapid, 
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TLR-2 dependent but transient up-regulation of inflammatory genes in primary TECs 
through an NF-κB dependent pathway. 
2.2 Introduction 
Mycoplasma gallisepticum (M. gallisepticum) is an avian respiratory pathogen 
causing severe inflammation of the trachea, air sacs and lungs, especially in the presence 
of a co-infection [1-3]. This pathogen is known to invade, survive and multiply inside a 
variety of non-phagocytic cells such as chicken RBCs, HeLa cells, and chicken 
fibroblasts, [4-9]. In addition, M. gallisepticum is known to colonize many extra-
pulmonary tissues including blood, heart, spleen, liver and brain [4, 5, 7, 8, 10]. Indikova 
et al. (2013) suggested that invasion may occur at the air sac, where the mucosal barrier is 
quite thin [7]. However, there is yet no clear evidence that M. gallisepticum invades 
tracheal epithelial cells in vivo [unpublished observations], as it predominantly colonizes 
the mucosal surface and only rarely is found inside phagocytic vacuoles [11]. 
Nonetheless, the organism orchestrates immuno-pathological changes in the tracheal 
mucosa marked by infiltration of heterophils, macrophages and lymphocytes [2, 12, 13] 
soon after attachment and colonization of the respiratory surface.  
A previous study from our laboratory reported up-regulation of several chemokines 
including lymphotactin, CXCL-13, RANTES and MIP-1β in chicken trachea isolated 
from live birds within 24 hours of experimental M. gallisepticum infection [12]. These 
chemokines are primarily produced by macrophages, lymphocytes and NK cells; cell 
types not found in large numbers in the uninfected tracheal mucosa [14-19]. However, 
chemokines and cytokines that are produced by epithelial cells upon infection are known 
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for their ability to recruit phagocytic cells and lymphocytes into infected tissues [20]. Due 
to the protective layer of mucus, it is not clear if the initial interaction of mycoplasmas 
with the host epithelium is driven by viable organisms or microbial components such as 
lipoprotein-bearing membrane fragments or both, although substantial evidence supports 
the notion that the initial “pathogen perception” occurs upon interaction of various 
PAMPs with TLRs [20-24]. Previous studies conducted using other mycoplasma species 
suggest an important role for epithelial cells in inflammation. For example, A549 human 
lung epithelial cells increase their production of IL-8, TNF-α, IL-1β, and IL-6 following 
Mycoplasma pneumoniae (M. pneumoniae) exposure [25]. Similarly, cultured human 
endocervical epithelial cells exposed to Mycoplasma genitalium (M. genitalium) secreted 
several pro-inflammatory chemokines and cytokines including IL-6, IL-7, IL-8, MCP-1 
and GM-CSF [26-28].  
Due to the lack of a peptidoglycan cell wall or outer membrane, mycoplasmas do not 
possess lipopolysaccharides (LPS), lipotechoic acid or flagella. Even though certain 
mycoplasmas are known for production of exotoxins, like the M. pneumoniae CARDS 
toxin or Mycoplasma arthritidis mitogen MAM [29-32], the majority of mycoplasmas 
including M. gallisepticum are not known to produce or secrete any exotoxin. Their 
surface-exposed membranes are composed of a single lipid bi-layer with numerous 
embedded integral and peripheral proteins and membrane anchored lipoproteins [33-35]. 
Phase and antigenic variable expression of these membrane lipoproteins provides a 
mechanism of immune evasion [36-46], and the importance of these molecules is 
reflected by the percentage of the mycoplasma genome devoted to lipoproteins. For 
example, in M. gallisepticum about 10% of the genome is devoted to vlhAs (variable 
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lipoprotein hemagglutinins) which includes 38 genes with signature vlhA features and 5 
pseudogenes possessing vlhA sequence homology [47].  
Mycoplasma lipoproteins are known to partition into the Triton X-114 detergent 
phase during phase partitioning. This detergent phase fraction may also contain other 
hydrophobic proteins besides lipoproteins [48], and therefore has been termed “lipid 
associated membrane proteins" (LAMPs) [48-51]. In other mycoplasma species, the 
detergent phase fraction containing these LAMPs was found to activate NF-κB via TLR-
1, 2, 6 as well as CD-14 via a MyD88 pathway, and induce expression of pro-
inflammatory cytokines in monocytes and macrophages [43, 48, 50-53]. Recently, it was 
also found that mycoplasma LAMPs are capable of activating the NLRP3 inflammasome 
resulting in the induction of IL-1β [54]. Several other studies found that lipoproteins 
purified from the TX-114 fraction induce inflammatory responses via TLR-2 or TLR-1/2 
andTLR-2/6 heterodimers [28, 34, 48-50, 55-59]. However, the vast majority of these in-
vitro studies were performed using leukocytes even though the initial interactions 
between mycoplasma membrane components and host cells occur at the mucosal surface 
upon contact with epithelial cells [28, 60, 61]. Thus, we hypothesized that LAMPs of M. 
gallisepticum ligate TLR-2 on respiratory epithelial cells, resulting in the up-regulation of 
inflammatory chemokine and cytokine genes via an NF- κB dependent pathway. To test 
this hypothesis, M. gallisepticum LAMPs were incubated with primary chicken tracheal 
epithelial cells in culture (TEC) or tracheae ex vivo to examine differential gene 
expression and to determine if the response is mediated via TLR-2 ligation. Similar 
studies using viable organisms were conducted to assess the relative contribution of 
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LAMPs to early inflammatory events, using the low passage, adherent and virulent M. 
gallisepticum strain Rlow or a high passage, non-adherent and non-virulent strain, Rhigh.  
2.3 Materials and Methods 
Bacterial Strains and Culture Conditions 
M. gallisepticum low passage virulent strain Rlow (passage 17) and high passage non-
virulent strain Rhigh ( passage 167) were cultured at 37
o C in modified Hayflicks medium 
supplemented with 10% horse serum and 5% yeast extract until mid-log phase as 
determined by acid-mediated shift of phenol red dye from red to orange, as previously 
described [2]. Cell density was measured and a mycoplasma concentration of 0.9 x 108 
to1.6 x 108 cfu (colony forming unit) per milliliter, approximately mid-log phase, was 
used.  
Isolation of TX-114 phase proteins 
M. gallisepticum strains Rlow and Rhigh were grown to mid-log phase as previously 
described and pelleted by centrifuging at 10,000 x g for 20 minutes. Pellets were washed 
twice with PBS and suspended in 750µl of TS buffer (10mM Tris, 150 mM NaCl, pH 
7.5) containing 1mM PMSF and 1% TX-114 and rocked for 30 minutes at 4oC, followed 
by centrifugation at 10,000 x g at 4oC for 5 minutes. The soluble phase was transferred to 
a new tube and incubated at 37oC with rocking for 10 minutes and then centrifuged for 5 
minutes at room temperature to separate the aqueous and detergent phases. 500 µl of TS 
buffer containing 1mM PMSF and 1% TX114 was added to the detergent phase obtained 
in the previous step and thoroughly mixed and incubated for 15 min at 4oC followed by 
10 min at 37oC with rocking followed by centrifugation for 5 minutes (at 10,000x g) at 
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room temperature. The detergent phase was collected and the previous step was repeated 
to obtain the final detergent phase. The LAMPs were precipitated overnight at -20oC with 
2 volumes of methanol and centrifuged at 15,000 xg for 20 minutes. Precipitated protein 
was suspended in PBS by sonication for 30 seconds at output 5 using Biosonik ultrasonic 
disintegrator (Bronwill Scientific; Rochester, NY). Protein concentration was determined 
by Quick StartTM Bradford protein assay kit (Bio Rad; Hercules, CA) according to 
manufacturer’s instructions.  
Cell culture and exposure/stimulation 
A primary chicken tracheal epithelial cell culture was established based upon two 
previously described protocols [62, 63]. Five-week-old female specific pathogen free 
chicken tracheae were obtained from SPAFAS (Charles River Laboratories; Mansfield, 
CT) in sterile PBS (phosphate-buffered saline) containing 1X penicillin-streptomycin to 
inhibit bacterial and fungal growth. The tracheae were rinsed twice in DMEM 
(Dulbecco’s modified eagles medium) (Gibco®, Life technologies; Grand Island, NY) 
under sterile conditions. After removal of the surrounding adipose and muscular tissues, 
tracheae were cut into 2cm pieces and incised vertically. They were then twice rinsed for 
5 minutes in PBS/DTT (Dithiothreitol) (Sigma Aldrich; St. Louis, Missouri) (0.0385 g 
DTT- in 50ml 1X PBS) to remove non-adherent mucus. The pieces were then rinsed 
twice with PBS and DMEM. To dissociate the epithelial cells from the underlying 
connective tissue, about 3-4 tracheal pieces were placed in a T25 flask containing 25ml 
dissociation solution [DMEM 50ml, protease type XIV 0.14g (Sigma Aldrich), DNAse 
0.01g (Sigma Aldrich) and antibiotic/antimycotic 1X (Gibco®, Life technologies)]. The 
flasks were gently shaken for 15 minutes at 37C to slightly loosen the cells. 10% FBS 
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(Gibco®, Life technologies) was added to block protease activity after incubation. The 
tracheae were washed twice with fresh DMEM. The luminal surface of tracheae was 
scraped gently with a sterile scalpel in a petri dish containing fresh DMEM to obtain the 
epithelial cells. Cells were centrifuged at 1,250 rpm for 5 minutes to remove media. The 
epithelial cells were placed in 10 ml dissociation solution for 10 minutes at 37C and then 
pipetted up and down several times to dissociate clumped cells. 10% FBS was added to 
the dissociation solution to stop the reaction. Cells were centrifuged at 1,250 rpm for 5 
min to remove residual enzymes and washed twice with PBS. Cells were suspended in 
DMEM supplemented with 10% FBS and plated in a T75 flask for 4 hours to allow 
adherent cells (primarily fibroblasts and macrophages) to attach. The unattached cells 
were collected and precipitated by centrifugation at 1,250 rpm for 5 minutes and 
suspended in ATE medium [DMEM F-12+ Glutamax, (Gibco®, Life technologies) 10% 
FBS (Gibco®, Life technologies), 10% chick embryo extract (US Biologicals; Salem, 
MA), 1X MEM non-essential amino acids (NEAA) (Gibco®, Life technologies), 1X 
antibiotic/antimycotic (Gibco®, Life technologies)], counted on a hemocytometer and 
plated on 5% matrigel (BD Biosciences; San Jose, CA) coated T12.5 flasks. Exposure 
studies were done at 96 hours post-plating when the flasks reached 70-80% confluence, at 
which time they were exposed to either 5x108 cfu (roughly equal to 500 multiplicity of 
infection (MOI) live strain Rlow, Rhigh as previously described [64] or LAMPs isolated 
from each strain at a concentration of 5µg/mL. This concentration was based on 
preliminary studies where 5µg/mL and 50 µg/mL LAMPs showed comparable potency 
(based on changes in gene regulation) and roughly equivalent to 500 MOI (5x108 cfu) 
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live mycoplasma. All experiments were done with 6 replicates each for 1.5, 6, and 24 
hours.  
Whole tracheal exposure 
Tracheae from 5-week-old female specific-pathogen free white leghorn chickens 
were obtained from SPAFAS (Charles River Laboratories; Mansfied, CT) in sterile PBS 
containing 1X penicillin-streptomycin to inhibit bacterial and fungal growth. Surrounding 
adipose tissues were removed and tracheae were cut into 0.5 inch pieces by vertical 
incision and rinsed 3 times with PBS and DMEM under sterile conditions. The tracheae 
were exposed to either 109 cfu M. gallisepticum strains Rlow and Rhigh or 10 µg/mL 
LAMPs from either strain for 1.5 or 6 hours in ATE medium at 370C, 5% CO2. After 
exposure, tracheae were digested in dissociation solution (described previously) for 15 
minutes at 370C and immediately placed on ice. Epithelial cells from the luminal surface 
of tracheal pieces were lightly scraped using a sterile scalpel. Epithelial cells were then 
preserved in RNA later (Ambion, Life Technologies; Grand Island, NY) at 40C for future 
RNA isolation (detailed below). All exposures were done with 6 replicates each for 1.5, 
and 6 hours.  
Immunocytostaining 
Tracheal epithelial cells and DF-1(Chicken embryonic fibroblast) cells grown on 
coverslips were fixed with 10% formalin and permeablized with 0.25% Triton X-100. 
Immunocytochemistry was performed using primary monoclonal anti-vimentin antibody 
(Sigma-aldrich) and anti E-cadherin antibody (Millipore; Billerica, MA) at a 
concentration of 1:200. Fluorescence-tagged secondary antibodies used were goat anti 
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mouse IgG FITC (Sigma-aldrich) for visualization of vimentin and Alexa Fluor® 546 
Goat Anti-Rabbit IgG (H+L) (Life Technologies; Grand Island, NY) for visualization of 
E-cadherin at a 1:250 dilution. Vectashied® HardSet mounting medium containing DAPI 
(4′, 6-Diamidino-2-phenylindole) (Vector Laboratories; Burlingame, CA) was used to 
mount cells on a slide for imaging. Images of immunostaining were captured using a 
Nikon A1R Spectral Confocal Microscope (Nikon Instruments Inc.; Melville, NY).  
Signaling inhibitors 
Tracheal epithelial cells were incubated with either 3 µg/mL Rlow LAMPs or 5 µg/mL 
Rhigh LAMPs in the presence or absence of signaling inhibitors. TLR-2/4 signaling 
inhibitor OxPAPC (oxidated 1-palmitoyl-2-arachidonyl-sn- glycero-3-
phosphorylcholine), TLR-4 inhibitor CLI-095, and NF-κB inhibitor Celastrol were 
purchased from Invivogen (Invivogen; San Diego, CA). Cells were co-incubated with 
either 10 µg/mL or 30 µg/mL OxPAPC and LAMPs for 6 hours, in accordance with the 
manufacturer’s instruction. Cells were pre-incubated with 1 µg/mL CLI-095 for 6 hours 
before exposure to LAMPs and then further incubated for 6 hours after LAMP exposure. 
Pre-incubation of cells with 5 µM Celastrol for 30 minutes was done before LAMP 
exposure for 6 hours. All experiments were performed with 6 replicates each. 
RNA isolation and cDNA synthesis  
Total RNA was extracted from cells using TRIzol reagent (Life Technologies) and 
purified using RNeasy mini columns according to the manufacturer’s instructions 
(Qiagen; Valencia, CA). On-column DNase digestion was done using RNase free DNase 
(Qiagen;). RNA quality and quantity was assessed using the Agilent 2100 Bioanalyzer 
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with the RNA pico kit (Agilent technologies; Mendon, MA). All RNA samples had a 
RNA integrity number of 8 or more. 500 ng of RNA from individual samples was reverse 
transcribed using iScriptTM reverse transcription supermix for RT-qPCR (Bio Rad; 
Hercules, CA) according to the manufacturer’s recommendation, and 2µg RNA was 
reverse transcribed for PCR reaction to assess epithelial-specific gene expression. 
Microarray  
Agilent chicken gene expression microarray slides were utilized (Agilent 
technologies). Total RNA (50 ng) was utilized as starting material for microarray 
hybridization. Four biological replicates for each of five exposure conditions utilized 
were: Rhigh, Rlow, Rhigh LAMPs, Rlow LAMPs and media control. Dye swap technical 
replicates were created for each biological replicate totaling eight replicates for each 
exposure condition. The Agilent two-color microarray-based gene expression analysis 
protocol version 6.5 (http://www.genome.duke.edu/cores/microarray/services/agilent-
microarrays/documents/LIQA_G4140-90050_GeneExpression_Two_Color_v6.5.pdf) 
was followed. All incubations were performed utilizing the Applied Biosystem® 
Geneamp PCR system 9700 (Life Technologies). The Agilent two-color low-input quick 
amp labeling kit (Agilent technologies) was utilized for cDNA synthesis, in-vitro 
amplification and labeling of nucleic acids. Purification of labeled cRNA was performed 
with the Qiagen RNeasy mini kit). Purified cRNA was fragmented using the Agilent gene 
expression hybridization kit (Agilent technologies). Microarray slides and hybridization 
gasket were assembled in a hybridization chamber (Agilent technologies). Samples were 
placed in a rotating hybridization oven set to 10 rpm at 65°C for 17 hours. Microarray 
slides were scanned using a GenePix 4000B laser scanner (Molecular Devices; 
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Sunnyvale, CA) following the instructions in the GenePixPro 7 user guide. Feature 
extraction was performed utilizing GenePixPro 7 software (Molecular Devices). 
Microarray images were visually inspected for quality control of features (spots on 
microarray slide that have spotted oligonucleotide probes). Background fluorescence of 
each feature was calculated as the mean of the five closest negative control features. Each 
channel’s background-corrected median fluorescence value was used in an intensity-
based analysis utilizing Agilent GeneSpring (v12.5) software (Agilent technologies). 
Quantile normalization was performed on all the background-corrected intensity values 
and samples were clustered according to their original exposure group. Features were 
removed if they were at saturating intensity or flagged “bad” in the aforementioned visual 
inspection. Genes were removed from downstream analysis if <80% of the features 
representing a gene were already excluded following preprocessing of data. Genes with 
duplicate or triplicate features on the microarray were grouped and their mean values 
were used for a gene-level analysis. Quantile normalization was then performed on the 
gene-level in-silico experiment. All microarray datasets have been deposited into Gene 
Expression Omnibus database repository, accession number GSE61520 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61520).  
Polymerase Chain Reaction 
PCR reactions were performed using cDNA to identify expression of epithelial cell-
specific genes in tracheal epithelial cell cultures using GoTaq® Green master mix 
(Promega; Madison, WI). Cycle conditions were as follows: 94oC for 3 minutes, 94oC for 
30 seconds, 58oC for 30 seconds, 72oC for 1 minute. Step 2 to 4 was repeated 30 times. 
65 
 
Final extension was performed at 72oC for 10 minutes. Primers for the epithelial cells 
specific genes are listed on Table 2.1.  
Real time quantitative PCR (RT-qPCR) 
Primers specific for chicken genes were designed using Primer 3 input version 0.4.0 
(http://frodo.wi.mit.edu/) or as described in Mohammed et al [12] (Table 2.2). RT-qPCR 
was performed using 1µl of cDNA from the reverse transcription reaction using iTaqTM 
universal SYBR® green supermix (Bio Rad). Amplification was performed using an 
Applied Biosystem® 7900 HT (Life Technologies) by incubating samples at 50oC for 2 
minutes, 95 oC for 1 min, followed by 40 cycles of 95 oC for 15 seconds and 58–60 oC 
(depending on Tm values of specific primers) for 60 seconds. Melt curve analysis was 
performed to confirm that a single, product-specific amplification had occurred. A 
stepwise temperature gradient was used (65-95 oC) with 0.5 oC increments and 2 sec/step. 
Amplicon sizes were confirmed by agarose gel electrophoresis. The reference gene for all 
real time reactions was GAPDH. Absolute fold change compared to the media controls 
were calculated using the Ct values based upon the following equation:  
[( ) ( ) ]
     2  2 Control TestCt gene of  interest  Ct GAPDH Ct gene of  interest  Ct GAPDH
Test
Fold change Ct
Control
   
 
 
 
   Gel electrophoresis was performed using a 0.8% agarose gel to determine the product 
size for each gene.  
SDS PAGE and proteomics 
200 µg of Rlow LAMPs was separated by SDS-PAGE. Briefly, laemelli buffer was 
added to the LAMPs to 1:1 ratio and incubated at 70oC for 10 minutes. The LAMPs were 
then ran in 4-20% mini TGX gel (Bio-Rad) with tris glycine buffer. Bands were then 
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stained using coomassie blue reagent (Bio-Rad) for 1 hour and destained overnight at 4oC 
in distilled water. Total 13 bands were cut and homogenized in 1% SDS in a tissuelyzer 
and centrifuged to remove the polyacrylamide gel. Each fraction was precipitated using 5 
volumes of acetone at -20oC overnight. TECs in 24 well plates at 70-80% confluency 
were exposed to LAMPs from each band at a concentration of 1µg/mL.   
For proteomic characterization of Rlow LAMPS, each of the 13 gel bands were cut and 
prepared for LC-MS using in gel tryptic digestion kit (Thermo Scientific; Waltham, MA). 
All LC-MS based characterizations were done at Mass Spectrometry Facility of 
University of Connecticut, Department of Chemistry with help from Dr. Xudong Yao and 
Dr. Fu You-Jun.  
Statistical analysis 
All statistical analyses were performed using the Statistical Analysis Software (SAS) 
program Version 9.2 (SAS Institute; Inc Cary, NC). Multiple pairwise comparisons of 
mRNA fold differences were analyzed using the mixed design analysis of variance 
(ANOVA) with repeated measures, with mRNA fold difference being the dependent 
variable and treatments or time being the independent variables. Post hoc mean 
comparison analyses were performed using least square means. Results were denoted as 
fold change ± SEM. Significant differences were denoted as * = P< 0.05, **= P <0.01, 
*** = P < 0.001.  
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2.4 Results 
Tracheal epithelial cell culture and immunocytostaining 
 Primary tracheal epithelial cell cultures were established based on published methods 
[62, 63]. Confirmation was performed using PCR amplification of epithelial cell specific 
genes and morphological examination based on E-cadherin staining patterns. A chicken 
embryonic fibroblast cell line (DF-1) was used as a negative control. E-cadherin staining 
was observed only at the contact points between cells, which is typical of epithelial cell 
morphology. Very few cells in the TEC culture stained for vimentin, suggesting an 
extremely low level of fibroblast contamination. As a positive control, DF-1 chicken 
fibroblast cells stained positively for vimentin and not for E-cadherin (Figure 2.1A-D, 
Figure 2.2). 
Microarray analysis – global gene expression profile 
Microarray analysis of chicken tracheal epithelial cells at 1.5 hours post-exposure 
identified a total of 166, 43, 55 and 38 genes differentially regulated ≥ 5-fold (p≤0.05) 
after exposure to either live Rlow and Rhigh, or to 5µg/mL Rlow or Rhigh LAMPs respectively 
(Figure 2.3). 23 genes were commonly up-regulated ≥ 5-fold in TECs in all four 
exposure groups, which included many inflammatory chemokine and cytokine genes 
(Figure 2.3; indicated by the asterisk*). Gene ontology analysis of commonly up-
regulated genes (≥2-fold) identified categories such as immune system processes, signal 
transduction, regulation of apoptosis and stress response (Table 2.3, Figure 2.4). 
Exposure to viable Rlow resulted in differential expression of 110 unique genes by a factor 
of ≥ 5- fold (p≤0.05) (Table 2.4) whereas only six or fewer genes were unique in TECs 
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exposed to Rhigh, Rlow LAMPs or Rhigh LAMPs (Figure 2.3). Pathway analysis identified 
differential expression of genes in the TLR signaling pathway, with 12 out of 70 genes 
commonly up-regulated in all four exposure groups. Other pathways of note included the 
TNF-α/NF-κB signaling, apoptosis, and type II interferon pathways (Table 2.5 and 
Figure 2.5).  
Differential gene expression in Rlow, Rlow LAMP, Rhigh and Rhigh LAMP exposed 
TECs 
A concentration of 5 µg/mL LAMPs optimally induced the expression of IL-1β and 
CCL-20, which was roughly comparable to the up-regulation induced by 500 MOI (5x108 
cfu) live mycoplasma (data not shown). mRNA transcripts of six immune response 
associated genes up-regulated in TECs upon exposure to each of the four treatments were 
validated by RT-qPCR at 1.5, 6 and 24 hours. TECs’ expression of IL-12p40, IL-1β and 
IL-6 peaked at 1.5 hours post-exposures in all four exposure groups and waned 
significantly thereafter in contrast to CCL-20 and nitric oxide synthase-2 (NOS-2) which 
peaked at 6 hours and returned to near baseline levels within 24 hours. IL-8 expression 
peaked at 6 hours in Rlow exposed TECs, however Rhigh and Rlow LAMP exposed TECs 
exhibited the highest level of IL-8 gene expression at 1.5 hours (p≤0.01 and p ≤ 0.001) 
(Figure 2.6A-D). Five out of six genes (IL-6, IL-8, IL-12p40, CCL-20 and NOS-2) were 
expressed at significantly higher levels in Rlow exposed TECs when compared to TECs 
exposed to Rhigh or LAMPs isolated from either strain, at one or more time point (Figure 
2.7A-E). IL-1β gene expression in TECs did not significantly differ between any of the 
four exposures at any time point (Figure 2.7F). We also observed that Rlow LAMP 
exposed TECs had a significantly higher level of the IL-12p40 gene expression when 
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compared to TECs exposed to Rhigh LAMP at 1.5 hours (p≤0.05) (Figure 2.7A) and CCL-
20 when compared to TECs exposed to Rhigh or Rhigh LAMP at 1.5 and 6 hours (p≤0.01 
and p≤0.001) (Figure 2.7D).  
Differential gene expression in TECs by mycoplasma LAMPs in the presence of 
signaling inhibitors 
OxPAPC, a TLR-2 and 4 signaling inhibitor, reduced expression of all 6 genes in a 
concentration dependent manner (Figure 2.8A-F). IL-12p40 gene expression was 
reduced by more than 2-fold in TECs exposed to LAMPs when incubated with OxPAPC 
at 30 µg/mL when compared to both Rlow (P< 0.05) and Rhigh LAMP (P<0.01) exposed 
TECs (Figure 2.8A). IL-1β and CCL-20 gene expression were reduced by more than 5-
fold compared to TECs exposed to Rlow (P< 0.001) or Rhigh (P< 0.001) LAMPs in the 
absence of the inhibitor (Figure 2.8B, E). IL-8 (P< 0.001), IL-6 (P< 0.01) and NOS-2 
(P< 0.001) gene expression was also significantly reduced by approximately 2-3 fold 
(Figure 2.8C, D, and F). No difference was observed upon exposure to CLI-095, a 
selective TLR-4 inhibitor, for any of the genes analyzed in this study, supporting the 
hypothesis that M. gallisepticum LAMPs signal via TLR-2 and not TLR-4 (Figure 2.8A-
F). In the presence of Celastrol, an NF-κB inhibitor, cell signaling was abolished entirely 
(comparable to control levels) in TECs exposed to any of the four treatments (P<0.001 
for all six genes analyzed) (Figure 2.8A-F).  
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Comparison of gene regulation in Rlow, Rlow LAMP, Rhigh and Rhigh LAMP exposed 
tracheal epithelial cells ex vivo 
mRNA transcripts of all six genes were also up-regulated in tracheal epithelial cells 
isolated from whole tracheal tissues exposed ex vivo to live Rlow, Rhigh or the LAMPs 
isolated therefrom. Most genes followed a similar pattern of expression as seen in the in 
vitro experiments. IL-12p40 was expressed at a significantly higher level in Rlow exposed 
trachea at both time points compared to others, and CCL-20 was significantly higher in 
Rlow exposed trachea than all others at 1.5 hours (p≤0.001) (Figure 2.9A, 5B). IL-8 
expression was higher in both Rlow and Rhigh exposed trachea when compared to the 
LAMP exposed tracheae at both time points but IL-6 was found to be higher in the 
LAMP-exposed tissues (p≤0.001) at 1.5 hours and lower at 6 hours (p≤0.01, p≤0.05) 
when compared to tracheae exposed to live Rlow or Rhigh. Although IL-1β expression did 
not differ between any exposure groups at 1.5 hours, at 6 hours tracheae exposed to the 
live mycoplasma were found to express IL-1β at a higher level than either LAMP-
exposed tracheae (p≤0.001 for Rlow , p≤0.05 for Rhigh). NOS-2 expression did not differ 
between any exposure groups at any time point (Figure 2.9A, 5B).  
Micro RNA and IL-10 gene expression 
Expression analysis of four miRNA genes including mir-21, mir-146a, mir-146b, and 
mir-146c1, as well as IL-10 was assessed in TECs exposed to either LAMPs or live 
organisms. IL-10 gene expression in all TECs peaked at 1.5 hours, concomitant with the 
pro-inflammatory genes (Figure 2.10A). Expression analysis of miRNAs showed that 
miRNA146a increased over time in TECs exposed to live mycoplasmas; however in 
TECs exposed to the LAMPs from both strains, miRNA146a expression peaked at 6 
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hours (Figure 2.10B). Expression of miRNA21, miRNA146b and miRNA146c1 did not 
differ from media controls at any time point in any exposure group (data not shown). 
IL-1β expression by TECs upon exposure to SDS-PAGE separated LAMPs 
LAMPs from Rlow were separated using 1D SDS-PAGE and 13 distinct band of 
various molecular weight were obtained (Figure 2.11A). TECs at 70-80% confluency on 
24 well plates were exposed to 1µg/mL of LAMPs from each of the 13 fractions obtained 
from SDS-PAGE separation. IL-1β expression were up-regulated significantly in TECs 
upon exposure to LAMPs from 10 out of 13 bands (2 fold or more). 5 or more fold up-
regulation of IL-1β were observed during exposure to LAMPs from bands of 110kd, 
100kd, 64kd, 52kd, 23kd and 20kd (Figure 2.11B). When proteomic characterization of 
each of the 13 bands was done, several M. gallisepticum lipoproteins were identified as 
well as several hypothetical proteins (Table 2.6). The 6 bands that showed highest 
activity contained many lipoproteins, including VlhA 3.03, the primary vlhA expressed 
by M. gallisepticum strain Rlow as well as virulence associated lipoprotein MslA, being 
the two most common lipoproteins in these bands (Table 2.6).  
2.5 Discussion 
Bacterial cell envelope components such as LPS, lipotechoic acid, peptidoglycan, 
flagella and lipoproteins are well characterized PAMPs that interact with host cell pattern 
recognition receptors such as TLRs, thereby contributing in part to the inflammation that 
ensues post-infection [20, 43, 65]. With the exception of lipoproteins, M. gallisepticum is 
devoid of these PAMPs, yet is able to initiate a robust inflammatory response marked by 
infiltration of leukocytes to the submucosa, often in absence of tissue invasion [2, 12, 13, 
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66, 67]. Mycoplasma lipoproteins are well known for their pro-inflammatory properties, 
initiated upon TLR ligation and NF-κB activation [34, 48-51, 55, 56, 68]. However, the 
vast majority of studies examining these effects have focused on monocytes/macrophages 
maintained in culture rather than epithelial cells, the primary site of mycoplasma 
attachment and colonization [11, 69].  
Previous studies from our laboratory in which live birds were exposed to M. 
gallisepticum intra-tracheally reported alterations in inflammatory gene expression in 
whole tracheal tissue [12]. The current study is novel in that it reports interaction of M. 
gallisepticum lipid associated membrane proteins, a mixture of lipoproteins, specifically 
with host airway epithelial cells.  
A study by Walter et al (2001) reported that IL-12p40 was expressed by airway 
epithelial cells during viral tracheobronchitis [70, 71]. We also observed IL-12p40 
mRNA to be significantly up-regulated both in TECs and epithelial cells from tracheae 
upon exposure to live mycoplasma or LAMPs within 1.5 hours of exposure. But this 
signal waned rapidly thereafter, suggesting that IL-12p40 acts as an early, but not 
sustained, inflammatory event. IL-1β and IL-6 mRNA expression were also up-regulated 
and followed similar kinetics to that observed with IL-12p40. mRNA expression of two 
important chemokines, CCL-20 and IL-8 were also significantly up-regulated in 
epithelial cells in-vitro and ex-vivo after exposure to LAMPs or live organisms, as was 
NOS-2. These molecules are known for their ability to chemo-attract and activate 
leukocytes at the site of infection [72-77]. Several other inflammation associated genes, 
including TLR-15, were up-regulated to a lesser degree in TECs in all four exposure 
groups (Table 2.3, RT-qPCR data not shown). This cytokine and chemokine expression 
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profile is in keeping with earlier studies that reported M. pneumoniae and M. genitalium 
mediated production of IL-8, TNF-α, IL-1β, IL-6 IL-7, MCP-1 and GM-CSF from 
epithelial cells [25-28]. 
A previously published study from our laboratory however, reported down-regulation 
of IL-12p40, IL-8, IL-1β, and CCL-20 mRNA in tracheal tissues at day-1 post-infection, 
whereas chemokines like MIP-1β, CXCL-13, RANTES and lymphotactin were found to 
be up-regulated [12]. As this later set of chemokines are known to be produced primarily 
by macrophages, lymphocytes and NK cells [14-19], types of cells not found in large 
numbers in normal tracheal mucosa, we believe transient but robust expression of 
chemokines and cytokines like IL-12p40, IL-8, IL-6, IL-1β, and CCL-20 by tracheal 
epithelial cells may be responsible for initially attracting the inflammatory cells into the 
tracheal submucosa. However these signals appear to be transient and subsequent 
signaling events appear to involve a unique set of inflammatory genes not observed in 
epithelial cells.  
In the current study we also observed that Rlow was by far the most potent stimulus for 
initiating differential gene expression by epithelial cells when compared to live Rhigh or 
LAMPs from either strain. TECs exposed to Rlow not only up-regulated inflammatory 
genes to a significantly higher extent, but up-regulated more than a hundred additional 
unique genes by ≥5 fold. The Rhigh strain is non-virulent as it lacks several virulence 
determinant proteins of Rlow, especially GapA and CrmA [7, 78] two significant 
cytadhesion-associated proteins homologous to P1 and P40/P90 of M. pneumoniae [78-
84]. The significantly diminished cytadhesion capability of Rhigh [7, 82, 85, 86], may 
explain the reduced differential gene expression induced by this strain. Subtle differences 
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in gene expression observed between the LAMPs prepared from Rlow and Rhigh may also 
be explained by the differences identified by Szczepanek et al. involving 29 mutations in 
the variable GAA repeat region associated with phase variable expression of vlhA genes 
between these two strains [86].  
When TECs were exposed to LAMPs in the presence of OxPAPC, a competitive 
inhibitor of lipoprotein and LPS mediated signaling via TLR-2 and TLR-4 respectively 
[87], expression of all six genes was significantly reduced. However in the presence of 
CLI-095, a selective TLR-4 inhibitor, no changes in gene expression were observed. 
When TECs were exposed to Celastrol, an NF-κB inhibitor [88], LAMP-mediated gene 
expression was completely abrogated. This observation is in keeping with previous 
studies from other mycoplasma species in which LAMP-induced inflammation was 
mediated upon TLR-2 ligation and activation of NF-κB [28, 34, 49-51, 53, 55, 56]. 
Moreover, these observations apply to early time-points post-exposure, in a highly 
relevant cell population.  
The kinetics of inflammatory gene expression in the current study was found to be 
rapid, peaking at either 1.5 hours or 6 hours, and then waning by 24 hours. As modulation 
of host responses is often accompanied by concurrent pro- and anti-inflammatory 
mechanisms [89], we hypothesized that a compensatory, homeostatic mechanism may be 
working in concert with the inflammatory response. Upon NF-κB activation, certain anti-
inflammatory genes and micro RNA’s are expressed that participate in the homeostatic 
regulation of inflammatory responses. For example, miRNA-146a, which is induced by 
LPS via NF-κB activation, down-regulates IRAK-1 and TRAF-6 and in turn suppresses 
further activation of NF-κB [90]. miRNA146a also negatively regulate TLR-2 signaling 
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[91]. miRNA-21, on the other hand can promote IL-10 production by regulating PDCD4 
(programmed cell death 4), an inhibitor of IL-10 production [90]. We observed miRNA-
146a expression to be increasingly up-regulated until 24 hours in TECs exposed to either 
Rlow or Rhigh in contrast to the pattern observed upon exposure to LAMPs, which peaked 
at 6 hours and waned thereafter, likely due to the lack of LAMP re-stimulation [91]. No 
difference in expression was observed for miRNA146b, miRNA146c1 or miRNA21. 
Conversely, the anti-inflammatory cytokine IL-10 showed no reciprocal relationship to 
pro-inflammatory gene expression, but was significantly up-regulated by the epithelial 
cells initially upon exposure to live Rlow and the LAMPs (but not Rhigh). IL-10 is known 
to selectively inhibit nuclear localization of NF-κB by blocking IκB kinase activity and 
inducing nuclear translocation and DNA-binding of the repressive p50-p50 homodimer 
[92, 93]. Therefore, miRNA-146a and in part IL-10 may play a role in regulating the 
over-exuberant pro-inflammatory response observed during M.gallisepticum infection.  
When proteomic characterization of Rlow LAMPs were done 10 out of 13 bands up-
regulated IL-1β significantly with 6 of them up-regulating IL-1β by more than 5 fold. 
MslA, a significant virulence associated lipoprotein [30] was found in 4 of the 6 bands 
and 3 other bands showing significant activity. The primary VlhA of M. gallisepticum 
strain Rlow, VlhA 3.03 a 64 kd protein was also found in 3 out of 6 bands and was found 
to be the most abundant lipoprotein in the LAMPs. These results suggest that MslA and 
VlhA 3.03 are possibly two major immunogenic lipoproteins of M. gallisepticum, 
however more sophisticated studies are required to confirm these preliminary findings.  
Taken together our data suggest that M. gallisepticum LAMPs have potent 
inflammatory properties and can mediate changes in gene expression in chicken tracheal 
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epithelial cells almost immediately upon exposure. However, the response appears to be 
transient in nature likely due to host compensatory mechanisms. Thus, continuous 
LAMP-mediated stimulation by adherent, replicating mycoplasma may be necessary to 
sustain the response. Studies using chemical inhibitors of specific signaling pathways 
indicated that mycoplasma LAMPs ligate TLR2 on TECs and activate NF-κB resulting in 
downstream expression of several pro-inflammatory chemokines and cytokines. Among 
the up-regulated genes are chemokines and cytokines known for leukocyte chemo-
attraction and activation, consistent with the immunopathology associated with infection. 
Our data also support the notion that the virulent Rlow strain possesses additional 
mechanisms of initiating inflammatory responses in tracheal epithelial cells beyond that 
mediated by LAMPs alone. 
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2.8 Figure Legends: 
Figure 2.1: Primary chicken tracheal epithelial cell culture (TEC)  
Primary chicken tracheal epithelial cells were isolated and cultured as described in the 
Methods section. 1A: Primary chicken tracheal epithelial cells at 100X magnification. 
1B: Confirmation of tracheal epithelial cell identity both in vitro and freshly isolated (ex 
vivo) from tracheae after ex-vivo exposure: PCR amplified epithelial cell specific genes 
from cDNA in agarose gel, compared to chicken embryonic fibroblast (DF-1) cells. 1C: 
Tracheal epithelial cells stained for E-cadherin and Vimentin at (400X magnification). 
Left panel shows TECs at different filter setting Blue (DAPI) for nuclear staining, Green 
(FITC) for Vimentin and Red (AlexaFluor® 546) for E-cadherin, right panel shows 
merged picture for all filters. 1D: DF-1 fibroblast cells stained for E-cadherin and 
Vimentin at 400X magnification. Left panel shows DF-1 cells at different filter setting; 
Blue (DAPI) for nuclear staining, Green (FITC) for Vimentin and Red (AlexaFluor® 
546) for E-cadherin; right panel shows merged picture for all filters. 
Figure 2.2: Original agarose gels photos of amplified products of epithelial cell 
specific genes  
1A: Confirmation of tracheal epithelial cells in culture in vitro using amplification of 
epithelial cell specific genes compared to chicken embryonic fibroblast (DF-1) cells. 1B: 
Confirmation of epithelial cell specific genes in freshly isolated epithelial cells from 
tracheae after ex-vivo exposure. 
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Figure 2.3: Distribution of differentially regulated genes in TECs (>5 fold) 
Differentially regulated genes (≥ 5 fold) in tracheal epithelial cell after exposure to 
live Rlow , Rhigh or LAMPs isolated from either strain 1.5 hours after exposure. The star (*) 
in the Figure 2.represent commonly up-regulated genes upon all four exposures, from 
which six follow up genes were chosen. n=8 (4 biological replicates x2 dye swap 
technical replicates) for all microarray experiments.  
Figure 2.4: Distribution of differentially regulated genes in TECs (>2 fold) 
Differentially regulated genes (≥ 2 fold) in tracheal epithelial cells after exposure to 
live Rlow , Rhigh or LAMPs isolated from either strain for 1.5 hours. n=8 (4 biological 
replicates x2 dye swap technical replicates) for all microarray experiments. 
Figure 2.5: TLR- Signaling pathway 
Toll like receptor signaling network: Common genes up-regulated in TECs exposed 
to Rlow, Rhigh, Rlow LAMP or Rhigh LAMP are depicted in yellow boxes.  
Figure 2.6: Kinetic analysis of differentially regulated genes encoding inflammatory 
chemokines and cytokines  
Differential gene expression in TECs exposed to Rlow, Rlow LAMP, Rhigh or Rhigh 
LAMP at 1.5, 6 and 24 hours respectively. Samples normalized to housekeeping gene 
GAPDH and un-exposed TECs as control. n=6 for all experiments. Results are denoted as 
fold change ± SEM with all control values set at 1. Significant differences denoted as * = 
P< 0.05, **= P <0.01, *** = P < 0.001. A: mRNA fold difference in Rlow exposed cells 
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B: mRNA fold difference in Rhigh exposed cells. C: mRNA fold difference in Rlow LAMP 
exposed cells. D: mRNA fold difference in Rhigh LAMP exposed cells.  
Figure 2.7: Differential gene expression in TECs post-exposure  
mRNA fold difference in TECs exposed to Rlow, Rlow LAMP, Rhigh or Rhigh LAMP at 
1.5, 6 and 24 hours respectively. Samples normalized to housekeeping gene GAPDH and 
un-exposed TECs as control. n=6 for all experiments. Results are denoted as fold change 
± SEM with all control values set at 1. Significant differences denoted as * = P< 0.05, 
**= P <0.01, *** = P < 0.001. A: IL-12p40 mRNA B: IL-8 mRNA C IL-6 mRNA D: 
CCL-20 mRNA E. NOS-2 mRNA. F: IL-1β mRNA.  
Figure 2.8: Differential gene expression in TECs exposed to LAMPs in the presence 
of signaling inhibitors.  
Epithelial cells were exposed to LAMPs isolated from Rlow or Rhigh in the presence or 
absence of signaling inhibitors for 6 hours. Samples were normalized to the housekeeping 
gene GAPDH and un-exposed TECs served as control. n=6 for all experiments. Results 
are denoted as fold change ± SEM with all control values set at 1.Significant differences 
denoted as * = P< 0.05, **= P <0.01, *** = P < 0.001. A. IL-12p40. B. IL-1β. C. IL-8. D. 
IL-6. E. CCL-20. F. NOS-2.  
Figure 2.9: Differential gene expression in tracheal epithelial cells after ex-vivo 
exposure to LAMPs  
Comparison of mRNA fold difference in tracheal epithelial cells from tracheal 
explant exposed to Rlow, Rlow LAMP, Rhigh or Rhigh LAMP at 1.5 and 6 hours respectively. 
Samples normalized to housekeeping gene GAPDH and un-exposed tracheae as control. 
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n=6 for all experiments. Results are denoted as fold change ± SEM with all control values 
set at 1. Significant differences denoted as * = P< 0.05, **= P <0.01, *** = P < 0.001. A: 
mRNA fold difference of all genes at 1.5 hours B: mRNA fold difference of all genes at 6 
hours 
Figure 2.10: RT-qPCR analysis of miRNA and IL-10 differential expression in 
TECs  
Epithelial cells were exposed to Rlow, Rlow LAMP, Rhigh or Rhigh LAMP at 1.5, 6 and 
24 hours respectively. Samples were normalized to housekeeping gene GAPDH and un-
exposed TECs as control. n=6 for all experiments. Results are denoted as fold change ± 
SEM with all control values set at 1. Significant differences denoted as * = P< 0.05, **= 
P <0.01, *** = P < 0.001. A: mRNA fold difference of IL-10 in TECs at all three time 
points post exposure. B: mRNA fold difference of miRNA-146a in TECs at all three time 
points post exposure.  
Figure 2.11: SDS-PAGE fractionation of Rlow LAMPs and IL-1β expression by 
TECs in presence of various SDS-PAGE fractions of Rlow LAMPs 
A: SDS-PAGE separation of Row LAMPs identified 13 distinct bands. B: mRNA fold 
difference of IL-1β in TECs upon exposure to 1µg/mL LAMPs from each band obtained 
during SDS-PAGE separation.  
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2.9 Tables:  
Table 2.1: Epithelial gene specific primers 
Gene 
ID 
Primer Name Sequence 5’-3’ 
395209 
Retinoic acid responder Forward 
Retinoic acid responder Reverse 
ACA TCA ACT CCC ACG AGG CGT CC 
ACT GCT GCC AAC AAT GGC CAA GC 
408039 
Keratin 14 Forward 
Keratin 14 Reverse 
CAC TGC CAG CCC GCT GTG CT 
ACC TTG TCC AGG TAG GCG GCC 
 
407779 Keratin 5 Forward 
Keratin 5 Reverse 
TGC TGC TTT CCT GCT GCT CAG C 
ACG GTC ACT TCA TGG ATG CCA CC 
 
414833 
Cytochrome P-450 2C45 Forward 
Cytochrome P-450 2C45 Reverse 
CCA CGT GGG AGA TGT TGC TCC TG 
TGG CAG CAA ACT CAT CCG CAC G 
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Table 2.2: Gene specific primers for RT-qPCR 
Primer Name Sequence 5’-3’ 
GAPDH Forward ATT CTA CAC ACG GAC ACT TCA 
GAPDH Reverse CAC CAG TGG ACT CCA CAA CAT A 
IL-12p40 Forward TGAAGGAGTTCCCAGATGC 
IL-12p40 Reverse CGTCTTGCTTGGCTCTTTATA 
IL-1β Forward GCT GGA ACT GGG CAG AT 
IL-1β Reverse GGT AGA AGA TGA AGC GGG TC 
IL-8 Forward GTG CAT TAG CAC TCA TTC TAA GTT 
IL-8 Reverse GGC CAT AAG TGC CTT TAC G 
IL-6 Forward CCT GTT CGC CTT TCA GAC CTA 
IL-6 Reverse AGT CTG GGA TGA CCA CTT C 
IL-10 Forward AGAGATGCTGCGCTTCTACA 
IL-10 Reverse GCTTGATGGCTTTGCTCC 
CCL-20 Forward GCC AGA AGC TCA AGA GGA TG 
CCL-20 Reverse TCC AGA AGT TCA ACG GTT CC 
NOS-2 Forward TGA TCT TTG CTG CCA AAC AG 
NOS-2 Reverse TCC TCT GAG GGA AAA TGG TG 
miRNA-146a Forward GAGAACTGAATTCCATGGGTTG 
miRNA-146a Reverse TCCAAGCTGAAGAACTGAGC 
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Table 2.3: Differentially expressed genes (≥2-fold, p-value ≤0.05) common in TECs 
exposed to Rlow, Rhigh, Rlow lipoprotein and Rhigh lipoprotein: analyzed for gene ontology 
hierarchal clustering.  
Entrez 
Gene ID 
Gene Name 
Fold Change in TECs exposed to 
Rlow Rhigh 
Rlow 
lipoprotein 
Rhigh 
lipoprotein 
Immune system processes 
768950 CD80 molecule 2.96 4.77 2.44 4.02 
395082 Chemokine (C-C motif) ligand 20 55.34 11.67 43.92 12.98 
417465 Chemokine (C-C motif) ligand 5 2.63 2.65 2.38 2.65 
396330 Interferon regulatory factor 7 6.57 5.21 5.44 4.22 
395196 Interleukin 1, beta 9.89 7.86 6.75 5.65 
404671 Interleukin 12B 207.80 71.80 194.67 78.21 
395337 Interleukin 6 42.33 30.57 27.31 20.95 
396495 Interleukin 8 22.92 20.72 17.87 19.44 
396093 Nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells inhibitor, alpha 
5.00 4.15 5.00 3.62 
417247 Similar to TL1A; tumor necrosis 
factor (ligand) superfamily, 
member 15 
4.22 14.47 4.08 10.33 
421219 Toll-like receptor 15 2.75 2.53 3.69 2.11 
770778 Gallus gallus interleukin 28B 14.34 11.44 10.28 11.08 
Regulation of apoptosis 
395673 BCL2-related protein A1 4.92 4.47 4.53 3.40 
423471 TNF receptor-associated factor 3 3.68 5.35 4.39 5.46 
374012 Baculoviral IAP repeat-containing 
2 
5.42 4.07 5.45 3.48 
395196 Interleukin 1, beta 9.89 7.86 6.75 5.65 
404671 Interleukin 12B 207.80 71.80 194.67 78.21 
417247 Similar to TL1A; tumor necrosis 
factor (ligand) superfamily, 
member 15 
4.22 14.47 4.08 10.33 
396033 Nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells 1 
2.55 2.08 2.58 2.02 
396093 Nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells inhibitor, alpha 
5.00 4.15 5.00 3.62 
417319 Phosphoinositide-3-kinase, 
regulatory subunit 5, p101 
6.34 3.27 5.17 3.01 
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Entrez 
gene ID 
Gene name 
Fold change in tecs exposed to 
Rlow Rhigh 
Rlow 
lipoprotein 
Rhigh 
lipoprotein 
Signal transduction 
419844 Ras association (ralgds/af-6) 
domain family 5 
5.03 3.80 4.24 3.98 
415790 Ras-related associated with 
diabetes 
4.88 3.03 4.27 3.25 
423471 Tnf receptor-associated factor 3 3.68 5.35 4.39 5.46 
422884 Tnfaip3 interacting protein 2 10.95 4.77 7.09 7.01 
769087 Angiopoietin-like 4 angptl4 7.27 2.66 5.90 2.17 
408036 Epiregulin 4.01 2.02 2.80 2.66 
395196 Interleukin 1, beta 9.89 7.86 6.75 5.65 
396033 Nuclear factor of kappa light 
polypeptide gene enhancer in b-
cells 1 
2.55 2.08 2.58 2.02 
396093 Nuclear factor of kappa light 
polypeptide gene enhancer in b-
cells inhibitor, alpha 
5.00 4.15 5.00 3.62 
423290 Similar to ras guanyl releasing 
protein 1 
2.25 3.89 3.58 3.50 
417247 Similar to tl1a; tumor necrosis 
factor (ligand) superfamily, 
member 15 
4.22 14.47 4.08 10.33 
416630 Suppressor of cytokine signaling 1 8.37 3.76 5.41 3.22 
421219 Toll-like receptor 15 2.75 2.53 3.69 2.11 
378803 Tumor necrosis factor receptor 
superfamily, member 11b 
(osteoprotegerin) 
2.59 2.09 2.40 3.32 
Response to stress 
395654 Heparin-binding egf-like growth 
factor 
6.66 4.39 5.22 3.61 
395196 Interleukin 1, beta 9.89 7.86 6.75 5.65 
395807 Nitric oxide synthase 2, inducible 10.53 3.68 8.41 3.94 
418404 Nuclear factor of kappa light 
polypeptide gene enhancer in b-
cells inhibitor, zeta 
10.24 17.96 12.14 15.32 
396424 Plasminogen activator, urokinase 7.15 16.65 7.95 14.86 
396451 Prostaglandin-endoperoxide 
synthase 2 
12.98 10.65 13.13 9.76 
421219 Toll-like receptor 15 2.75 2.53 3.69 2.11 
408036 Epiregulin 4.01 2.02 2.80 2.66 
404671 Interleukin 12b 207.80 71.80 194.67 78.21 
396093 Nuclear factor of kappa light 
polypeptide gene enhancer in b-
cells inhibitor, alpha 
5.00 4.15 5.00 3.62 
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Entrez gene 
ID 
Gene name 
Fold change in tecs exposed to 
Rlow Rhigh 
Rlow 
lipoprotei
n 
Rhigh 
lipoprotein 
Cell communication 
395820 Delta-like 1 (drosophila); 
similar to c-delta-1 
3.19 2.76 2.18 2.37 
408036 Epiregulin 4.01 2.02 2.80 2.66 
395337 Interleukin 6 42.33 30.57 27.31 20.95 
420628 Sorting nexin 10 3.71 2.02 3.31 2.25 
374168 Wingless-type mmtv 
integration site family, 
member 7a 
3.27 4.42 2.79 4.47 
Cell migration/locomotion 
395654 Heparin-binding egf-like 
growth factor 
6.66 4.39 5.22 3.61 
395196 Interleukin 1, beta 9.89 7.86 6.75 5.65 
404671 Interleukin 12b 207.8
0 
71.80 194.67 78.21 
396424 Plasminogen activator, 
urokinase 
7.15 16.65 7.95 14.86 
417465 Chemokine (c-c motif) ligand 
5 
2.63 2.65 2.38 2.65 
396495 Interleukin 8 22.92 20.72 17.87 19.44 
Regulation of cell proliferation 
768950 Cd80 molecule 2.96 4.77 2.44 4.02 
408036 Epiregulin 4.01 2.02 2.80 2.66 
395654 Heparin-binding egf-like 
growth factor 
6.66 4.39 5.22 3.61 
395196 Interleukin 1, beta 9.89 7.86 6.75 5.65 
404671 Interleukin 12b 207.8
0 
71.80 194.67 78.21 
395337 Interleukin 6 42.33 30.57 27.31 20.95 
395807 Nitric oxide synthase 2, 
inducible 
10.53 3.68 8.41 3.94 
396093 Nuclear factor of kappa light 
polypeptide gene enhancer in 
b-cells inhibitor, alpha 
5.00 4.15 5.00 3.62 
396424 Plasminogen activator, 
urokinase 
7.15 16.65 7.95 14.86 
396451 Prostaglandin-endoperoxide 
synthase 2 
12.98 10.65 13.13 9.76 
417247 Similar to tl1a; tumor necrosis 
factor (ligand) superfamily, 
member 15 
4.22 14.47 4.08 10.33 
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Entrez 
gene ID 
Gene name 
Fold change in tecs exposed to 
Rlow Rhigh 
Rlow 
lipoprote
in 
Rhigh 
lipoprotein 
Response to stimulus 
395082 Chemokine (c-c motif) ligand 20 55.34 11.67 43.92 12.98 
417465 Chemokine (c-c motif) ligand 5 2.63 2.65 2.38 2.65 
395654 Heparin-binding egf-like growth factor 6.66 4.39 5.22 3.61 
418812 Immunoresponsive 1 homolog (mouse) irg1 47.48 28.24 43.40 29.42 
396330 Interferon regulatory factor 7 6.57 5.21 5.44 4.22 
395196 Interleukin 1, beta 9.89 7.86 6.75 5.65 
404671 Interleukin 12b 207.8
0 
71.80 194.67 78.21 
395337 Interleukin 6 42.33 30.57 27.31 20.95 
396495 Interleukin 8 22.92 20.72 17.87 19.44 
395807 Nitric oxide synthase 2, inducible 10.53 3.68 8.41 3.94 
396093 Nuclear factor of kappa light polypeptide 
gene enhancer in b-cells inhibitor, alpha 
5.00 4.15 5.00 3.62 
418404 Nuclear factor of kappa light polypeptide 
gene enhancer in b-cells inhibitor, zeta 
10.24 17.96 12.14 15.32 
396424 Plasminogen activator, urokinase 7.15 16.65 7.95 14.86 
396451 Prostaglandin-endoperoxide synthase 2 12.98 10.65 13.13 9.76 
417247 Similar to tl1a; tumor necrosis factor (ligand) 
superfamily, member 15 
4.22 14.47 4.08 10.33 
421219 Toll-like receptor 15 2.75 2.53 3.69 2.11 
Receptor binding 
769087 Angiopoietin-like 4 angptl4 7.27 2.66 5.90 2.17 
395082 Chemokine (c-c motif) ligand 20 55.34 11.67 43.92 12.98 
417465 Chemokine (c-c motif) ligand 5 2.63 2.65 2.38 2.65 
395820 Delta-like 1 (drosophila); similar to c-delta-1 3.19 2.76 2.18 2.37 
408036 Epiregulin 4.01 2.02 2.80 2.66 
395654 Heparin-binding egf-like growth factor 6.66 4.39 5.22 3.61 
395196 Interleukin 1, beta 9.89 7.86 6.75 5.65 
404671 Interleukin 12b 207.8
0 
71.80 194.67 78.21 
395337 Interleukin 6 (interferon, beta 2) 42.33 30.57 27.31 20.95 
396495 Interleukin 8 22.92 20.72 17.87 19.44 
417247 Similar to tl1a; tnf (ligand) superfamily, 
member15 
4.22 14.47 4.08 10.33 
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Entrez 
gene ID 
Gene name 
Fold change in tecs exposed to 
Rlow Rhigh 
Rlow 
lipoprotein 
Rhigh 
lipoprotein 
Protein binding 
417247 Similar to tl1a; tumor necrosis 
factor (ligand) superfamily, 
member 15 
4.22 14.47 4.08 10.33 
423163 Similar to traf6; tnf receptor-
associated factor 6 
3.35 3.01 3.29 2.24 
420628 Sorting nexin 10 3.71 2.02 3.31 2.25 
416630 Suppressor of cytokine signaling 
1 
8.37 3.76 5.41 3.22 
421219 Toll-like receptor 15 2.75 2.53 3.69 2.11 
419088 Tsukushin 4.24 2.68 3.76 3.02 
378803 Tumor necrosis factor receptor 
superfamily, member 11b 
(osteoprotegerin) 
2.59 2.09 2.40 3.32 
396250 V-ets erythroblastosis virus e26 
oncogene homolog 2 (avian) 
2.53 2.75 2.13 2.43 
374168 Wingless-type mmtv integration 
site family, member 7a 
3.27 4.42 2.79 4.47 
Other genes 
420838 Cd83 molecule 5.98 4.53 5.63 3.75 
428492 F-box and leucine-rich repeat 
protein 7 
3.30 4.23 3.29 4.07 
420343 F-box protein 32 -2.95 -3.37 -3.59 -3.77 
422061 G protein-coupled receptor 116 3.57 3.99 3.68 3.21 
416546 Nadph oxidase organizer 1 31.41 11.36 27.79 11.96 
395138 St3 beta-galactoside alpha-2,3-
sialyltransferase 6 
3.33 4.85 3.07 4.08 
771693 Tnfaip3 interacting protein 3 5.04 2.69 5.87 2.81 
427985 Udp-gal:betaglcnac beta 1,3-
galactosyltransferase, polypeptide 
5 
2.21 3.42 2.56 3.78 
418422 Chromosome 3 open reading 
frame 52 
2.45 2.39 2.22 2.10 
417515 Deltex homolog 2 3.72 2.34 2.99 2.57 
769474 Family with sequence similarity 
83, member c 
2.77 3.92 2.42 3.78 
421747 Fyn-related kinase 3.17 3.69 2.62 3.57 
417968 Guanylate cyclase 2c 2.10 2.46 2.01 2.16 
422840 Heparan sulfate (glucosamine) 3-
o-sulfotransferase 1 
3.50 2.94 3.22 2.72 
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Entrez 
gene ID 
Gene name 
Fold change in tecs exposed to 
Rlow Rhigh 
Rlow 
lipoprotein 
Rhigh 
lipoprotein 
Other genes 
423723 Peptidylprolyl isomerase f 4.28 2.33 2.44 2.11 
423227 Phospholipase a2, group ive 2.45 2.65 3.18 2.44 
419262 Regulator of telomere elongation 
helicase 1 
2.78 3.65 2.27 2.95 
420628 Sorting nexin 10 3.71 2.02 3.31 2.25 
423477 Tumor necrosis factor, alpha-
induced protein 2 
9.29 4.90 8.42 4.39 
421684 Tumor necrosis factor, alpha-
induced protein 3 
4.98 4.25 4.28 3.21 
420942 Uridine phosphorylase 1 2.64 2.37 2.27 2.90 
419618 Zinc finger ccch-type containing 
12a 
4.16 3.33 4.22 3.16 
396384 Interferon regulatory factor 1 
(irf1) 
5.66 5.48 4.73 5.07 
416325 Granulocyte-macrophage colony-
stimulating factor 
5.16 8.70 5.20 9.57 
395827 Cytochrome p450, family 24, 
subfamily a, polypeptide 1 
(cyp24a1) 
3.06 3.17 3.30 3.17 
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Table 2.4: Differentially expressed unique genes in Rlow exposed TECs (≥5-fold, p-value 
≤0.05) (Excludes unknown genes listed as finished cDNA clones) 
Entrez Gene 
ID 
Gene Name 
Fold change in 
Rlow exposed 
TECs 
   
395888 NK2 transcription factor related, locus 3 87.83 
428065 Protocadherin 8 65.12 
 
Partial mRNA for immunoglobulin heavy chain variable region, clone 
U11B3. 
33.71 
418236 Parvin gamma 29.20 
429104 Cyclin-dependent kinase inhibitor 2C 28.81 
427105 POLR3G polymerase (RNA) III (DNA directed) polypeptide G (32kD) 19.60 
374049 Tumor protein D52-like 1 19.52 
378791 Reticulon 1 19.15 
414343 Gal 9 15.95 
374004 Myogenin (myogenic factor 4) 13.33 
416953 
Member RAS oncogene family similar to small GTP-binding protein 
Rab36 
12.48 
424940 Cholinergic receptor, nicotinic, delta 11.74 
424171 G6PC2 glucose-6-phosphatase, catalytic, 2 9.32 
428714 
Probable tRNA threonylcarbamoyladenosine biosynthesis protein YwlC-
like 
7.55 
408183 Cytochrome P450, family 26, subfamily A, polypeptide 1 7.25 
427503 FSD2 fibronectin type III and SPRY domain containing 2 7.10 
428247 HTR3A 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic 7.04 
373928 Peroxisome proliferator-activated receptor gamma 6.88 
429283 Distal-less homeobox 1 6.36 
426186 Transmembrane protein 106C 6.26 
768668 Arylacetamide deacetylase-like 4-like 6.13 
396260 Mature avidin 6.07 
396114 Pyrimidinergic receptor P2Y, G-protein coupled, 6 5.95 
396300 Kainate binding protein 5.87 
427718 Leukemia inhibitory factor 5.78 
395725 Deoxyribonuclease I 5.77 
422307 Immune-responsive gene 1 protein-like 5.69 
415820 Hepatic nuclear factor 4beta 5.63 
416996 Inositol polyphosphate-5-phosphatase J 5.61 
422219 Interleukin 13 receptor, alpha 2 5.39 
417505 
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 7 
5.34 
768877 SAG S-antigen; retina and pineal gland (arrestin) 5.19 
428191 Ciliary rootlet coiled-coil, rootletin 5.18 
427028 Olfactory receptor 14J1 like 5.13 
429337 Apelin receptor 5.10 
419844 Ras association (RalGDS/AF-6) domain family 5 5.03 
430670 Chymotrypsin C 5.03 
419751 Glutamate receptor, ionotropic, kainate 4 5.01 
421686 Interleukin 20 receptor, alpha 5.01 
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Table 2.5: Pathway analysis of differentially regulated genes  
Analysis performed using GeneSpring (v12.5), within genes that are differentially 
expressed ≥2-fold (p-value ≤0.05).  
Pathway 
No. of genes from different pathways up-
regulated in TEC’s exposed to: 
Total no. 
of genes 
in 
pathway Rlow Rhigh 
Rlow 
LAMP 
Rhigh 
LAMP 
Toll-like receptor signaling 
pathway 
17 15 13 13 70 
TNF-alpha NF-kB 
Signaling Pathway 
10 9 11 10 157 
Adipogenesis 14 7 4 4 100 
Senescence and Autophagy 10 8 7 7 73 
EGFR1 Signaling Pathway 8 4 5 2 148 
MAPK signaling pathway 5 7 4 5 123 
Apoptosis 5 6 5 6 65 
Type II interferon signaling 
pathway 
6 4 4 4 22 
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Table 2.6: Proteomic characterization of Rlow LAMPs separated by SDS-PAGE 
Sample 
Peptide 
matches 
Sequence 
coverage 
Description 
Sample 1 
(175 kd) 
69 35% 
Hypothetical protein mga_0241 [Mycoplasma gallisepticum 
str. R(low)] 
 
50 24% Hypothetical protein [Mycoplasma gallisepticum str. F] 
 
6 8% 
Pts system glucose-specific transporter subunit iiabc 
[Mycoplasma gallisepticum str. R(low)] 
 
6 8% Ptsg_1 gene product [Mycoplasma gallisepticum str. F] 
 
4 6% M9 protein [Mycoplasma gallisepticum 
Sample 2 
(110 kd) 
47 37% 
Hypothetical protein mga_0319 [Mycoplasma gallisepticum 
str. R(low)] 
 
18 31% 
Vlha.3.03 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
10 15% 
Mycoplasma specific lipoprotein a [Mycoplasma gallisepticum 
str. R(low)] 
 
18 17% 
Hypothetical protein mga_0321 [Mycoplasma gallisepticum 
str. R(low)] 
 
9 12% 
Pts system glucose-specific transporter subunit iiabc 
[Mycoplasma gallisepticum str. R(low)] 
 
8 8% 
Putative oligopeptide abc transporter solute binding protein 
oppa [Mycoplasma gallisepticum str. R(low)] 
 
9 10% 
Hypothetical protein mga_0226 [Mycoplasma gallisepticum 
str. R(low)] 
 
5 14% 
Putative multidrug abc transporter permease component 
[Mycoplasma gallisepticum str. R(low)] 
 
4 4% 120kda membrane protein [Mycoplasma gallisepticum str. R] 
Sample 3 
(100 kd) 
49 43% 
Putative oligopeptide abc transporter solute binding protein 
oppa [Mycoplasma gallisepticum str. R(low)] 
 
33 42% 
Hypothetical protein mga_0226 [Mycoplasma gallisepticum 
str. R(low)] 
 
33 38% 120kda membrane protein [Mycoplasma gallisepticum str. R] 
 
28 22% 
Hypothetical protein mga_0321 [Mycoplasma gallisepticum 
str. R(low)] 
 
27 23% 
Hypothetical protein mga_0319 [Mycoplasma gallisepticum 
str. R(low)] 
 
5 6% 
Pts system glucose-specific transporter subunit iiabc 
[Mycoplasma gallisepticum str. R(low)] 
 
7 7% 
Cytadhesin protein gapa [Mycoplasma gallisepticum str. 
R(low)] 
 
5 7% M9 protein [Mycoplasma gallisepticum 
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Sample 
Peptide 
matches 
Sequence 
coverage 
Description 
Sample 4 
(75 kd) 
13 16% 
Pts system glucose-specific transporter subunit iiabc 
[Mycoplasma gallisepticum str. R(low)] 
 
12 17% 
Mycoplasma specific lipoprotein a [Mycoplasma gallisepticum 
str. R(low)] 
 
9 12% 
Vlha.5.03 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
8 13% 
Hypothetical protein mga_0267 [Mycoplasma gallisepticum 
str. R(low)] 
 
10 16% M9 protein [Mycoplasma gallisepticum 
 
7 11% Vlha protein [Mycoplasma gallisepticum 
 
7 12% Unknown [Mycoplasma gallisepticum 
 
6 6% 
Hypothetical protein mga_0648 [Mycoplasma gallisepticum 
str. R(low)] 
 
3 5% Vlha protein [Mycoplasma gallisepticum 
 
5 6% 
Vlha.1.07 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
Sample 5 
(70 kd) 
29 44% 
Vlha.4.07 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
32 49% 
Vlha.5.08 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
26 44% 
Vlha.3.03 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
23 32% 
Vlha.3.07 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
10 16% 
Vlha.4.07.1 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
7 11% 
Vlha.4.05 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
7 12% 
Vlha.4.01 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
4 8% 
Vlha.1.04 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
3 4% 
Vlha.1.03 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
3 4% 
Vlha.5.03 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
14 20% 
Mycoplasma specific lipoprotein a [Mycoplasma gallisepticum 
str. R(low)] 
 
10 14% 
Pts system glucose-specific transporter subunit iiabc 
[Mycoplasma gallisepticum str. R(low)] 
 
10 21% 
Hypothetical protein mga_0495 [Mycoplasma gallisepticum 
str. R(low)] 
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Sample 
Peptide 
matches 
Sequence 
coverage 
Description 
 5 6% 
Cell division protease ftsh-like protein [Mycoplasma 
gallisepticum str. R(low)] 
 
3 2% 
Hypothetical protein mga_0319 [Mycoplasma gallisepticum 
str. R(low)] 
 
4 7% 
Hypothetical protein mga_0267 [Mycoplasma gallisepticum 
str. R(low)] 
 
3 3% 
Hypothetical protein mga_0849 [Mycoplasma gallisepticum 
str. R(low)] 
 
3 3% 
Hypothetical protein mga_0045 [Mycoplasma gallisepticum 
str. R(low)] 
Sample 6 
(64 kd) 
53 66% 
Vlha.3.03 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
38 42% Haemagglutinin precursor [Mycoplasma gallisepticum s6] 
 
40 47% 
Variably expressed lipoprotein and hemagglutinin (vlha) 
family protein [Mycoplasma gallisepticum str. F] 
 
34 45% Haemagglutinin homologue [Mycoplasma gallisepticum s6] 
 
34 45% Pmga 1.2 [Mycoplasma gallisepticum 
 
33 45% Pmga1.2 a homologue of pmga [Mycoplasma gallisepticum 
 
30 34% Vlha protein [Mycoplasma gallisepticum 
 
30 38% 
Vlha.5.05 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
20 39% 
Hypothetical protein mga_0993 [Mycoplasma gallisepticum 
str. R(low)] 
 
17 35% 
Vlha.4.01 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
16 32% Hypothetical protein [Mycoplasma gallisepticum str. F] 
 
12 25% 
Vlha.3.02_1 gene product [Mycoplasma gallisepticum str. 
R(high)] 
 
12 17% 
Vlha.3.02 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
6 11% 
Hypothetical protein mga_0079 [Mycoplasma gallisepticum 
str. R(low)] 
 
5 8% 
Vlha.2.01 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
4 6% 
Vlha.5.02 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
4 7% 
Mycoplasma specific lipoprotein a [Mycoplasma gallisepticum 
str. R(low)] 
 
4 5% 
Vlha.4.07 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
4 5% 
Vlha.4.07.6 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
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Sample 
Peptide 
matches 
Sequence 
coverage 
Description 
Sample 7 
(52 kd) 
85 55% 
Mycoplasma specific lipoprotein a [Mycoplasma gallisepticum 
str. R(low)] 
 
85 46% Msla gene product [Mycoplasma gallisepticum str. F] 
 
22 38% 
Vlha.2.01 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
5 10% 
Vlha.5.13 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
8 16% 
Hypothetical protein mga_0267 [Mycoplasma gallisepticum 
str. R(low)] 
 
8 13% 
Hypothetical protein mga_1073 [Mycoplasma gallisepticum 
str. R(low)] 
 
7 11% 
Hypothetical protein mga_0416 [Mycoplasma gallisepticum 
str. R(low)] 
 
3 6% 
Phosphoenolpyruvate-protein kinase [Mycoplasma 
gallisepticum str. R(low)] 
 
6 9% M9 protein [Mycoplasma gallisepticum 
 
4 9% Pyruvate kinase [Mycoplasma gallisepticum str. R(low)] 
 
3 6% Adenosinetriphosphatase [Mycoplasma gallisepticum 
Sample 8 
(45 kd) 
44 38% 
Macrophage-activating lipoprotein-like protein [Mycoplasma 
gallisepticum str. R(low)] 
 
19 46% 
Dipeptide/oligopeptide/nickel abc transporter atp-binding 
protein dppd/oppd [Mycoplasma gallisepticum str. R(low)] 
 
19 23% 
Vlha.5.03 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
9 14% 
Vlha.4.05 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
7 12% 
Vlha.4.06 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
23 35% 
Hypothetical protein mga_0267 [Mycoplasma gallisepticum 
str. R(low)] 
 
19 30% 
Mycoplasma specific lipoprotein a [Mycoplasma gallisepticum 
str. R(low)] 
 
11 38% 
Translation longation factor tu (ef-tu) [Mycoplasma 
gallisepticum str. R(low)] 
 
10 17% 
Vlha.1.01 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
6 9% 
Vlha.1.04 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
9 15% 
Vlha.3.03 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
5 8% 
Vlha.4.07.6 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
13 30% 
Hypothetical protein mga_0878 [Mycoplasma gallisepticum 
str. R(low)] 
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Sample 
Peptide 
matches 
Sequence 
coverage 
Description 
 16 46% 
Glyceraldehyde-3-phosphate dehydrogenase [Mycoplasma 
gallisepticum str. R(low)] 
 
8 18% 
Hypothetical protein mga_0335 [Mycoplasma gallisepticum 
str. R(low)] 
 
4 12% 
Putative multidrug abc transporter permease component 
[Mycoplasma gallisepticum str. R(low)] 
 
8 22% 
Dnaj-like molecular chaperone [Mycoplasma gallisepticum str. 
R(low)] 
 
6 8% 
Cell division protease ftsh-like protein [Mycoplasma 
gallisepticum str. R(low)] 
 
3 7% 
Cysteinyl-trna synthetase [Mycoplasma gallisepticum str. 
R(low)] 
 
3 3% 
Pts system glucose-specific transporter subunit iiabc 
[Mycoplasma gallisepticum str. R(low)] 
 
5 4% 
Hypothetical protein mga_0319 [Mycoplasma gallisepticum 
str. R(low)] 
 
3 7% 
F0f1 atp synthase subunit beta [Mycoplasma gallisepticum str. 
R(low)] 
 
3 3% 
Vlha.1.05 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
15 34% 
L-lactate dehydrogenase [Mycoplasma gallisepticum str. 
R(low)] 
 
11 36% 
High affinity abc transporter protein hata [Mycoplasma 
gallisepticum str. R(low)] 
 
11 36% Hata gene product [Mycoplasma gallisepticum str. F] 
 
12 19% 
Vlha.3.03 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
8 16% 
Macrophage-activating lipoprotein-like protein [Mycoplasma 
gallisepticum str. R(low)] 
 
8 16% 
Macrophage-activating lipoprotein-like protein [Mycoplasma 
gallisepticum str. F] 
 
6 10% 
Vlha.5.03 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
7 22% 
Glyceraldehyde-3-phosphate dehydrogenase [Mycoplasma 
gallisepticum str. R(low)] 
 
7 22% Gapd gene product [Mycoplasma gallisepticum str. F] 
 
4 6% 
Pts system glucose-specific transporter subunit iiabc 
[Mycoplasma gallisepticum str. R(low)] 
 
10 31% 
Multidrug-like abc transporter atp-binding protein 
[Mycoplasma gallisepticum str. R(low)] 
 
7 14% 
Macrophage-activating lipoprotein-like protein [Mycoplasma 
gallisepticum 
 
7 18% 
Hypothetical protein mga_0878 [Mycoplasma gallisepticum 
str. R(low)] 
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Sample 
Peptide 
matches 
Sequence 
coverage 
Description 
 7 19% 
Phosphate abc transporter periplasmic phosphate binding 
protein [Mycoplasma gallisepticum str. R(low)] 
 
7 9% Pmga1.2 a homologue of pmga [Mycoplasma gallisepticum 
 
6 6% 
Vlha.5.05 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
4 7% 
Hypothetical protein mga_0267 [Mycoplasma gallisepticum 
str. R(low)] 
 
3 9% 
Recname: full=dna-directed rna polymerase subunit alpha; 
short=rnap subunit alpha; altname: full=rna polymerase 
subunit alpha; altname: full=transcrip 
 
3 9% 
Dna-directed rna polymerase subunit alpha [Mycoplasma 
gallisepticum str. R(low)] 
Sample 9 
(30 kd) 
10 19% 
Putative multidrug abc transporter permease component 
[Mycoplasma gallisepticum str. R(low)] 
 
10 14% 
Dipeptide/oligopeptide/nickel abc transporter permease 
dppb/oppb [Mycoplasma gallisepticum str. R(low)] 
 
8 28% 
Hypothetical protein mga_0244 [Mycoplasma gallisepticum 
str. R(low)] 
 
10 15% M9 protein [Mycoplasma gallisepticum 
 
8 28% Hypothetical protein [Mycoplasma gallisepticum str. F] 
 
9 23% 
Nuclease-like lipoprotein [Mycoplasma gallisepticum str. 
R(low)] 
 
8 13% Haemagglutinin precursor [Mycoplasma gallisepticum s6] 
 
7 12% 
Vlha.3.08 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
9 20% 
Hypothetical protein mga_0811 [Mycoplasma gallisepticum 
str. R(low)] 
 
8 20% Hypothetical protein [Mycoplasma gallisepticum str. F] 
 
6 15% 
Dipeptide/oligopeptide/nickel abc transporter permease 
dppc/oppc [Mycoplasma gallisepticum str. R(low)] 
 
7 13% Pmga1.2 a homologue of pmga [Mycoplasma gallisepticum 
 
7 13% Haemagglutinin homologue [Mycoplasma gallisepticum s6] 
 
7 13% Pmga 1.2 [Mycoplasma gallisepticum 
 
4 18% Adhesin pmga1.1 [Mycoplasma gallisepticum 
 
4 21% Pmga 1.1 [Mycoplasma gallisepticum 
 
5 8% 
Vlha.3.02 variable lipoprotein family protein [Mycoplasma 
gallisepticum str. R(low)] 
 
5 12% 
Vlha.3.02_1 gene product [Mycoplasma gallisepticum str. 
R(high)] 
 
3 11% 
Lema-family protein [Mycoplasma gallisepticum str. R(low)] 
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Sample 
Peptide 
matche
s 
Sequence 
coverage 
Description 
 3 11% Lema-family protein [Mycoplasma gallisepticum str. F] 
 
4 7% 
Cobalt abc transporter permease [Mycoplasma gallisepticum 
str. R(low)] 
 
4 7% Cbiq gene product [Mycoplasma gallisepticum str. F] 
Sample 10 
(23 kd) 
33 20% 
Mycoplasma specific lipoprotein a [Mycoplasma 
gallisepticum str. R(low)] 
 
31 20% Msla gene product [Mycoplasma gallisepticum str. F] 
 
10 17% 
Putative multidrug abc transporter permease component 
[Mycoplasma gallisepticum str. R(low)] 
 
8 33% Lema-family protein [Mycoplasma gallisepticum str. R(low)] 
 
6 20% Lema-family protein [Mycoplasma gallisepticum str. F] 
Sample 11 
(20 kd) 
12 29% 
Hypothetical protein mga_0913 [Mycoplasma gallisepticum 
str. R(low)] 
 
4 20% Ferritin-like protein [Mycoplasma gallisepticum str. R(low)] 
 
3 16% 
50s ribosomal protein l5 [Mycoplasma gallisepticum str. 
R(low)] 
 
2 3% 
Hypothetical protein mga_0267 [Mycoplasma gallisepticum 
str. R(low)] 
 
2 13% 
Hypothetical protein mga_0957 [Mycoplasma gallisepticum 
str. R(low)] 
 
3 10% 
Hypothetical protein mga_0119 [Mycoplasma gallisepticum 
str. R(low)] 
Sample 12 
(16 kd) 
5 10% 
Macrophage-activating lipoprotein-like protein [Mycoplasma 
gallisepticum str. R(low)] 
Sample 13 
(13 kd) 
5 10% 
Macrophage-activating lipoprotein-like protein [Mycoplasma 
gallisepticum str. F] 
 
2 13% 
Putative pts system glucose-specific transporter subunit iib 
ptsg [Mycoplasma gallisepticum str. R(low)] 
 
4 20% 
Organic hydroperoxide resistance protein [Mycoplasma 
gallisepticum str. R(low)] 
 
2 24% 
Hypothetical protein mga_0340 [Mycoplasma gallisepticum 
str. R(low)] 
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3.1 Abstract 
Mycoplasma gallisepticum (M. gallisepticum) mediates severe leukocyte influx into 
the tracheal submucosa after attachment and colonization of the epithelium. We recently 
reported that M. gallisepticum mediates up-regulation of chemokine and cytokine genes 
from chicken tracheal epithelial cells (TEC). The current study identifies how this 
interaction might lead to the further inflammatory process. Conditioned medium from 
TECs exposed to M. gallisepticum aided in macrophage (HD-11) chemotaxis with 
virulent Rlow strain being more efficient compared to non-virulent Rhigh. Co-culture assay 
of HD-11 cells with mycoplasma exposed TECs lead to up-regulation of several pro-
inflammatory genes in HD-11 cells including IL-1β, IL-6, IL-8, CCL20, MIP-1β, CXCL-
13 and RANTES. Rlow was found to be significantly more efficient in up-regulating these 
genes and aided in stable expression of chemokine genes. When HD-11 cells were 
exposed directly to live mycoplasmas they elaborated expression of all above mentioned 
genes as well as IFN-γ, but Rlow did not show higher efficiency in the response. However 
in both cases the average kinetic trend identified initial up-regulation of cytokine genes 
followed by dramatic decline within 24 hours, whereas chemokine genes except CCL-20 
remained significantly above control level until 24 hours. Taken together our data 
supports the notion that M. gallisepticum and host respiratory epithelial cell interaction 
leads to macrophage chemotaxis and activation leading to expression of inflammatory 
genes, and higher efficiency of Rlow in the process resonates with what is seen in vivo. 
The kinetics of expression of chemokine and cytokine genes may also suggest the 
mechanism of leukocyte infiltration to the tracheal submucosa without successful 
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clearance of the pathogen; however detailed in vivo studies are required to confirm the 
molecular events during M. gallisepticum pathogenesis.  
3.2 Introduction 
Mycoplasma gallisepticum is primarily known as an extracellular pathogen, however 
in recent years there has been an accumulation of evidences indicating invasion of a 
variety of cell types including RBCs, HeLa cells and fibroblasts [1-6]. The primary site of 
M. gallisepticum attachment and colonization is the respiratory epithelium; but no studies 
have reported invasive capabilities of this pathogen inside tracheal epithelial cells. In fact 
one study reported that M. gallisepticum was unable to invade ciliated tracheal epithelial 
cells but were sometimes found inside phagocytic vacuoles [7]. In our laboratory we also 
tried to identify cellular localization M. gallisepticum in chicken trachea by in-situ 
hybridization utilizing 16S riboprobes and identified their location to be extracellular 
(unpublished, see appendix).  
Due to the absence of a cell wall, mycoplasmas do not possess any endotoxin and 
despite being present in certain mycoplasmas, no exotoxins have been identified in M. 
gallisepticum [8-11]. However after attachment to the respiratory epithelium, M. 
gallisepticum mediates a severe inflammatory response, initially comprised of heterophils 
and macrophages and followed later by infiltrating lymphocytes including both B and T 
cells, into the submucosa. Previous studies reported that macrophages play a significant 
role in mycoplasma clearance, whereas polymorphonuclear leukocytes may in fact aid in 
dissemination of mycoplasma to other tissues [12, 13]. Both B and T cells were also 
found to play critical role in clearance and prevention of dissemination of mycoplasma 
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[13-15]. But as these events play important role in anti-mycoplasmal defense, they may 
also contribute to the significant immunopathology associated with the disease.  
 Chemokines and cytokines are often major factors in determining the outcome of 
immune responses and complex interplay between cells and cytokines often determine 
disease outcome. These molecules have been found to play significant role in 
mycoplasmal disease pathogenesis. Majority of studies conducted on interaction of 
mycoplasmas with macrophages and monocytes found expression and release of several 
chemokines and cytokines including but not limited to IL-4, IL-5, IL-6, IFN-γ, TNF-α, 
IL-1β, MIP-1β and presence these cytokines was highly correlated with the presence of 
gross inflammatory lesions [16-24].  Epithelial cell derived inflammatory mediators are 
known for their role in recruiting leukocytes to the site of infection [25] and during 
Mycoplasma genitalium infection, human cultured endocervical epithelial cells were 
found to produce IL-6, IL-7, IL-8, MCP-1 and GM-CSF [26-28] and Mycoplasma 
pneumoniae infection resulted in the release of IL-8 and RANTES from human nasal 
epithelial cells and up-regulation of IL-1β, IL-8 and TNF-α genes from A549 cells [29]. 
A recently published study from our laboratory identified, up-regulation of CCL-20, IL-
1β, IL-6, IL-8 and IL-12p40 in chicken tracheal epithelial cells within 1.5 hours of 
exposure to M. gallisepticum and their lipid associated membrane proteins (LAMP). 
Exposure to the virulent Rlow strain of M. gallisepticum was significantly more efficient 
in up-regulating these genes, and also up-regulated over 100 additional genes by 5- or 
more fold [30] compared to non-virulent Rhigh strain and LAMPs. However A previous 
study from our laboratory reported down regulation of CCL-20, IL-1β, IL-8 and IL-
12p40 in chicken trachea at day 1 upon experimental infection with M. gallisepticum with 
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CCL-20 and IL-12p40 expression remaining low throughout the time course and 
expression of IFN-γ, CXCL-13, RANTES, MIP-1β and lymphotactin to be up-regulated 
[31]. Since M. gallisepticum is able to induce this severe inflammatory response just by 
colonization of epithelial cell surface, without the presence of any endotoxin and known 
exotoxin led us to hypothesize that chemokines and cytokines produced by epithelial cells 
upon interaction with virulent M. gallisepticum aids in chemotactic migration of 
macrophages into the submucosa. And the above mentioned discrepancy in inflammatory 
gene expression also led us tohypothesize that the migrated macrophages in-turn express 
a unique set of inflammatory mediators which possibly results in an aberrant and 
sustained signal for further leukocyte recruitment leading to the observed 
dysregulated/“over-exuberant” immune response and the ensuing  immunopathological 
changes in the tracheal tissue. To test this hypothesis we utilized conditioned medium 
from epithelial cells exposed to a virulent and a non-virulent strain of M. gallisepticum, to 
identify their macrophage chemotactic properties in vitro. A co-culture study of 
macrophages with M. gallisepticum exposed tracheal epithelial cells was performed to 
identify macrophage activation leading to expression of inflammatory genes.  
3.3 Material and Methods 
Mycoplasma gallisepticum culture conditions  
M. gallisepticum, low passage virulent strain Rlow or high passage non-virulent strain 
Rhigh were grown in modified Hayflick’s medium until change of phenol red dye in media 
from red to orange or log phase. 0.7 X 108 – 1.3 X 108 cfu of mycoplasma per milliliter of 
culture were used in all studies to avoid use of overgrown culture.  
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HD-11 and tracheal epithelial cell culture 
Primary chicken tracheal epithelial cells (TEC) were cultured in ATE medium as 
previously described [30]. All exposures were done 72 hours post plating, when TECs 
reached about 70-80% confluency. Chicken HD-11 macrophage cell line was kindly 
provided by Dr. Steven C. Ricke at University of Arkansas, Department of Food Science. 
HD-11 cells were cultured in RPMI supplemented with 5% FBS and 5% chicken serum 
at 37oC with 5% CO2. HD-11 cells were plated at a concentration 10
4 cells/well in a 
6.5mm Transwell with 0.4µm Pore Polycarbonate Membrane Insert (Corning Inc.; 
Tewksbury MA) 18 hours prior to the co-culture assay. For other assays, HD-11 cells 
were plated at a concentration of 105 cells/well in 24 well plates 18 hours prior to 
exposure.  
Co-culture Study and exposure of HD-11 cells to live mycoplasma  
For the co-culture study chicken TECs were exposed to 108 cfu. M.gallisepticum 
(Approximately 500 MOI) strain Rlow or Rhigh or media alone for 2 hours to allow 
cytadherence. Supernatants containing unattached mycoplasmas were then removed and 
cells were washed thrice with sterile PBS. Cells were then supplemented with 500 µL 
fresh ATE medium and cultured for 6 hours. Transwell supports containing HD-11 cells 
were then placed over each well of the 24 well plates. Co-culture was allowed for 1.5, 6 
and 24 hours.  
128 
 
 
HD-11 cells were also exposed to 25, 50, 100 or 200 MOI of live M.gallisepticum 
strain Rlow or Rhigh per well as positive controls and cultured for 1.5, 6 and 24 hours. All 
experiments were done with 6 biological replicates. 
RNA isolation, cDNA synthesis and Real time quantitative PCR 
RNA was isolated from HD-11 cells using Qiagen RNeasy Mini (Qiagen; Valencia, 
CA) kit following manufacturer’s instruction. RNA quality and quantity were analyzed in 
Agilent 2100 Bioanalyzer using Agilent RNA 6000 Pico kit (Agilent technologies; 
Mendon,MA). All cDNA were synthesized from 1µg total RNA using iScript Reverse 
Transcription Supermix for RT-qPCR (Bio Rad; Hercules, CA). All RT-qPCR were 
performed using 1µL of cDNA with iTaq Universal SYBR Green Supermix (Bio Rad) in 
a total 20µL reaction. All amplfications were performed in a 7900HT Fast Real Time 
PCR system (Life Technogies; Grand Island,NY) using the protocol 50oC for 2 minutes, 
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95 oC for 1 min, followed by 40 cycles of 95 oC for 15 seconds and 58–60 oC (depending 
on Tm values of specific primers) for 60 seconds. Melt curve analysis was performed at 
65-95 oC with 0.5 oC increment and 2 sec/step. Agarose gel electrophoresis was used to 
confirm all amplicon sizes after RT-qPCR. Reference gene for all real time reactions was 
GAPDH and fold differences were determined using the ΔΔCT method. Primer 
sequences for all genes are listed in Table 3.1.  
Chemotaxis Assay 
TECs were exposed to 108 cfu (approximately 500 MOI) M.gallisepticum Rlow or 
Rhigh suspended in ATE medium and adherence was allowed for 2 hours. ATE medium 
alone was used as control. After 2 hours unattached mycoplasmas were removed along 
with the supernatant and the TECs were washed thrice with PBS. TEC culture was 
allowed for another 6 hours, and the culture medium was used as the conditioned 
medium. Chemotaxis assay was done using Neuro Probe 48 well micro-chemotaxis 
chamber and Neuro-probe 5µM pore size, polycarbonate membranes (Neuro Probe Inc.; 
Gaithersburg, MD). Chicken recombinant MIP-1β (Kingfisher Biotech; St Paul, MN) at a 
concentration of 100 ng/mL was used as positive control and DMEM-F12 as negative 
control. Conditioned medium from mycoplasma exposed TECs or control TECs were 
used for the assay. 30µL chemo-attractants were added in the bottom chamber and 50 µL 
HD-11 cells (2X107 cells/mL) were added on the top chamber. Chemotaxis assay was 
allowed to run for 4 hours at 370C incubator with 5% CO2. After completion of the assay, 
filters were collected, and cells that did not move towards the chemotaxis gradient 
through the pores were scraped. Cells that moved towards the chemotactic gradient 
through the pores were then stained using a Hema3 Stat Pack stain kit (Thermo Fisher 
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Scientific Inc.; Hudson, NH) according to manufacturer’s recommendations. The 
membrane was then air dried and cells were counted under a light microscope at 10X 
magnification. All experiments were performed with 6 biological replicates.  
Statistical Analysis 
All statistical analyses were performed using the Sigmaplot 11.0 software. Multiple 
pairwise comparison of number of cells migrated during the chemotaxis assay and 
mRNA fold differences during RT-qPCR studies were analyzed using one-way repeated 
measures ANOVA, using Shapiro-Wilk normality tests. Post-hoc pairwise multiple 
comparison analyses were done using Student-Newman-Keuls Method. Results were 
denoted as fold change ± SD. Differences were considered significant if p<0.05. 
Significant differences were denoted as * = P< 0.05, **= P <0.01, *** = P < 0.001.  
3.4 Results 
Chemotaxis Assay  
Chemotaxis assay was run as described in the methods section. Chicken recombinant 
MIP-1β and conditioned media from Rlow exposed TECs showed comparable levels of 
chemotactic activity towards HD-11 cells, with an average of 178 and 152 cells, which 
was significantly higher than the number of cells migrating in response to conditioned 
medium from Rhigh exposed TECs (p<0.001), conditioned medium from control TECs 
(p<0.001) and DMEM-F12 alone (p<0.001). Conditioned media from Rhigh exposed TEC 
chemoattracted larger numbers of cells than control TECs (p<0.05) and DMEM-F12 
(p<0.01). However no significant difference was observed between conditioned media 
obtained from control TECs and DMEM-F12 alone (Figure 3.1). 
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Gene expression in HD-11 cells upon Co-culture with mycoplasma exposed TECs 
Expression of IL-1β, IL-6, CCL-20, MIP-1β, CXCL-13, IL-8 and RANTES increased 
significantly in HD-11 cells during co-culture with both Rlow and Rhigh exposed TECs 
(Figure 3.2 A-H). Expression of IL-1β, IL-6 and CCL-20 peaked at 6 hours; reducing 
significantly thereafter in all samples (Figure 3.2 B-D). Expression of MIP-1β and IL-8 
peaked at 6 hours only during co-culture with Rhigh exposed TECs but stabilized after 6 
hours during co-culture with Rlow exposed TECs (Figure 3.2 E,G) and CXCL-13 peaked 
at 6 hours during co-culture with Rlow exposed TECs and at 1.5 hours during Rhigh (Figure 
3.2F). RANTES expression on the other hand had a stable expression after 6 hours in all 
samples (Figure 3.2H). IFN-γ expression did not differ between any time points during 
any exposure (Figure 3.2A). When the magnitude of gene expression were compared 
between HD-11 co-cultured with Rlow or Rhigh exposed TECs, expression of all 7 genes 
were found to be significantly higher in the Rlow exposed TEC for at least two or more 
time points (Figure 3.3 A-H).  
Gene expression in HD-11 cells upon exposure to live mycoplasma 
In HD-11 cells exposed to both live M. gallisepticum strains Rlow and Rhigh at various 
MOI, expression of IFN-γ, IL-1β and IL-6 and CCL20 peaked at 6 hours reducing 
significantly thereafter with IFN-γ and IL-6 reduced to baseline levels by 24 hours 
(Figure 3.4A-D and Figure 3.5A-D). MIP-1b, IL-8 and RANTES expression increased 
over time during all exposures (Figure 3.4E, G, H and Figure 3.5E, G, H). CXCL-13 
expression peaked at 6 hours reducing slightly by 24 hours, but still remained 
significantly up-regulated compared to control (Figure 3.4F and Figure 3.5F). No 
notable differences in gene expression were observed between exposures to various 
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MOIs. Surprisingly, when HD-11 cells were exposed to either live Rlow or Rhigh, unlike 
the previous studies Rlow did not up-regulate expression of genes at a higher level than 
Rhigh (Figure 3.6A-H).  
3.5 Discussion 
M. gallisepticum infection leads to inflammation of trachea, air sacs and lungs in 
chickens, and is associated with severe cytopathic effects and sub-epithelial infiltration 
leukocytes [14, 32, 33]. Cytadhesion to the respiratory epithelium is the primary and most 
critical step for this pathogenesis therefore cytadhesion deficient strains fail to induce a 
disease state in the host [34-36]. As invasive capabilities of M. gallisepticum into the 
tracheal epithelium have not yet been identified, it still remains elusive as to how this 
pathogen is able to mediate the severe inflammatory response just by adhering to the 
epithelium. We recently published a study identifying both Rlow and Rhigh strains to be 
able to up-regulate several inflammatory genes from tracheal epithelial cells. However 
Rlow was found to be more efficient in up-regulating inflammatory genes as well as 
differentially regulating several unique genes in tracheal epithelial cells not observed 
during Rhigh exposure [30]. The current study reports how M. gallisepticum and chicken 
tracheal epithelial cell interaction might play a role in the overall inflammatory response, 
and why virulent strains are more efficient in the process. 
During the chemotaxis assay we identified that conditioned medium from tracheal 
epithelial cells exposed to Rlow was significantly more efficient in chemoattracting 
macrophages when compared to conditioned medium from epithelial cells exposed to 
Rhigh. The co-culture study that was designed to identify effect of cell derived mediators 
from mycoplasma exposed epithelial cells on HD-11 cells, identified up-regulation of 
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several chemokine and cytokine genes including IL-1β, IL-6, IL-8, CCL-20, MIP-1β, 
CXCL-13 and RANTES but not IFN-γ and HD-11 cells co-cultured with Rlow exposed 
TECs showed significantly higher expression of all genes at two or more time points. We 
did not observe any significant changes in mRNA expression of IL-12p40 during any 
exposure at any time point. Activated macrophages are well known for their production 
of IL-12p40, which is essential for Th1 development [37], and are known to dramatically 
alter their secretory profile leading to production of chemokines and cytokines like IL-1β, 
IL-6, IL-8, MIP-1β, TNF-α, CXCL-13 and RANTES  [38-42]. Therefore lack of up-
regulation of IL-12p40 in this study and also during the previously published study 
identifying down regulation of this gene in chicken trachea [31] might suggest an 
improper activation of macrophages during M. gallisepticum infection. No observable 
difference in expression of IFN-γ, also suggest failure of epithelial cell derived mediators 
to properly activate macrophages [43]. However when HD-11 cells were exposed to live 
mycoplasma, IFN-γ along with all above mentioned genes were significantly up-
regulated in all samples, but surprisingly unlike the co-culture study, Rlow failed to induce 
higher gene up-regulation when compared to Rhigh and neither varied significantly 
between various MOIs.  
When the kinetics of expression were analyzed, expression of IL-1β, IL-6, CXCL-13 
and CCL-20 was found to peak at 6 hours, significantly reducing thereafter during co-
culture of HD-11 cells to both Rlow and Rhigh exposed TECs, however expression of MIP-
1β and IL-8 sustained at significantly high level in HD-11 cells co-cultured with Rlow 
exposed TECs and RANTES during both co-cultures. When HD-11 cells were exposed to 
various MOI of live M. gallisepticum Rlow or Rhigh, expression of Expression of IFN-γ and 
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IL-6 levels had a dramatic decrease after peak expression at 6 hours and reached baseline 
levels, and expression of IL-1β and CCL-20 was also significantly reduced by 24 hours. 
Expression of the other chemokine genes on the other hand stayed significantly above 
control level throughout the time course. 
Taken together these results support our notion that interaction of M. gallisepticum 
with host respiratory epithelial cells lead to macrophage chemotaxis and activation 
leading to expression of inflammatory chemokine and cytokine genes. Higher efficiency 
of Rlow exposed epithelial cells in all gene expression, as well as induction of sustained 
chemokine gene expression in macrophages also indicate why virulent strains are more 
efficient in establishing the inflammatory response, whereas non virulent strains fail to do 
so. Expression of inflammatory genes from macrophages therefore might not require 
invasion of live mycoplasma into the epithelium, and our results indicating both virulent 
and non-virulent mycoplasma at various MOIs, to be equally capable in differential gene 
expression from macrophages strengthens this notion. 
Whereas chemokines are known for their leukocyte recruitment properties, 
chemokines are involved in activation of leukocytes [44]. Therefore the observed kinetic 
trend of chemokine and cytokine gene expression in the study may indicate the severe 
immunopathology associated with M. gallisepticum infection in chickens without 
successful clearance of the pathogen, however more detailed in vivo studies are required 
to confirm these findings and better understand the cellular and molecular events during 
M. gallisepticum pathogenesis. 
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3.8 Figure Legends 
Figure 3.1: Chemotaxis assay results.  
Results denoted as mean of total number of cells migrated towards chemotactic 
gradient ± SD.  
Figure 3.2: Kinetic analysis of differentially regulated genes in HD-11 cells during 
co-culture study 
Kinetics of mRNA fold difference in HD-11 cells co-cultured with TECs exposed to 
Rlow or Rhigh at 1.5, 6 and 24 hours respectively. Samples normalized to housekeeping 
gene GAPDH and HD-11 co-cultured with un-exposed TECs as control. n=6 for all 
experiments. Results are denoted as fold change ± SD with all control values set at 1. 
Significant differences denoted as * = P< 0.05, **= P <0.01, *** = P < 0.001. A: IFN-γ 
mRNA B: IL-1β mRNA C IL-6 mRNA D: CCL-20 mRNA E. MIP-1β mRNA. F: 
CXCL-13 mRNA G: IL-8 mRNA H: RANTES mRNA  
Figure 3.3: Comparison of differential gene expression in HD-11 cells during co-
culture study 
mRNA fold difference comparison between HD-11 cells co-cultured with TECs 
exposed to either Rlow or Rhigh at 1.5, 6 and 24 hours respectively. Samples normalized to 
housekeeping gene GAPDH and HD-11 co-cultured with un-exposed TECs as control. 
n=6 for all experiments. Results are denoted as fold change ± SD with all control values 
set at 1. Significant differences denoted as * = P< 0.05, **= P <0.01, *** = P < 0.001. A: 
IFN-γ mRNA B: IL-1β mRNA C IL-6 mRNA D: CCL-20 mRNA E. MIP-1β mRNA. F: 
CXCL-13 mRNA G: IL-8 mRNA H: RANTES mRNA 
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Figure 3.4: Kinetic analysis of differentially regulated genes in HD-11 cells during 
exposure to live Rlow 
Kinetics of mRNA fold difference in HD-11 cells exposed to various MOI of Rlow at 
1.5, 6 and 24 hours respectively. Samples normalized to housekeeping gene GAPDH and 
unexposed HD-11 as control. n=6 for all experiments. Results are denoted as fold change 
± SD with all control values set at 1. Significant differences denoted as * = P< 0.05, **= 
P <0.01, *** = P < 0.001. A: IFN-γ mRNA B: IL-1β mRNA C IL-6 mRNA D: CCL-20 
mRNA E. MIP-1β mRNA. F: CXCL-13 mRNA G: IL-8 mRNA H: RANTES mRNA 
Figure 3.5: Kinetic analysis of differentially regulated genes in HD-11 cells during 
exposure to live Rhigh 
Kinetics of mRNA fold difference in HD-11 cells exposed to various MOI of Rhigh at 
1.5, 6 and 24 hours respectively. Samples normalized to housekeeping gene GAPDH and 
unexposed HD-11 as control. n=6 for all experiments. Results are denoted as fold change 
± SD with all control values set at 1. Significant differences denoted as * = P< 0.05, **= 
P <0.01, *** = P < 0.001. A: IFN-γ mRNA B: IL-1β mRNA C IL-6 mRNA D: CCL-20 
mRNA E. MIP-1β mRNA. F: CXCL-13 mRNA G: IL-8 mRNA H: RANTES mRNA 
Figure 3.6: Comparison of differential gene expression in HD-11 cells exposed to 
Rlow or Rhigh 
mRNA fold difference comparison between HD-11 cells exposed to various MOI of 
Rlow and Rhigh at 1.5, 6 and 24 hours respectively. Samples normalized to housekeeping 
gene GAPDH and unexposed HD-11 as control. n=6 for all experiments. Results are 
denoted as fold change ± SD with all control values set at 1. Significant differences 
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denoted as * = P< 0.05, **= P <0.01, *** = P < 0.001. A: IFN-γ mRNA B: IL-1β mRNA 
C IL-6 mRNA D: CCL-20 mRNA E. MIP-1β mRNA. F: CXCL-13 mRNA G: IL-8 
mRNA H: RANTES mRNA 
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3.9 Table 1: Gene specific primers for RT-qPCR 
Gene Name Primer sequence 5’-3’ 
GAPDH Forward ATTCTACACACGGACACTTCA 
GAPDH Reverse CACCAGTGGACTCCACAACATA 
IL-1β Forward GCTGGAACTGGGCAG AT 
IL-1β Reverse GGTAGAAGATGAAGCGGGTC 
IL-8 Forward GTGCATTAGCACTCATTCTAAGTT 
IL-8 Reverse GGCCATAAGTGCCTTTACG 
IL-6 Forward CCTGTTCGCCTTTCAGACCTA 
IL-6 Reverse AGTCTGGGATGACCACTTC 
CCL-20 Forward GCCAGAAGCTCAAGAGGATG 
CCL-20 Reverse TCCAGAAGTTCAACGGTTCC 
IFN-γ Forward TAGCTGACGGTGGACCTA 
IFN-γ Reverse CTCAGATATGTGTTTGATGTGCG 
MIP-1β Forward CTGCTTCACCTACATCTCCC 
MIP-1β Reverse GTCCTGTACCCAGTCGTT 
CXCL-13 Forward GGACCTCCCGAAGCTGAA 
CXCL-13 Reverse TCTGCCTTTCCACGGATACAT 
RANTES Forward TATTTCTACACCAGCAGCAAATG 
RANTES Reverse GCAGACACCTCAGGTCC 
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Chapter IV 
SUMMARY 
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4.1 Study I 
Mycoplasma gallisepticum-mediated respiratory inflammation in chickens is 
associated with accumulation of leukocytes in the tracheal submucosa. However the 
molecular mechanisms underpinning these changes are not yet well understood. The first 
study was based on the hypothesis that the inflammatory events are initiated upon 
ligation of mycoplasma lipid associated membrane proteins (LAMP) to TLRs expressed 
on chicken tracheal epithelial cells (TEC).  
Microarray analysis identified that TECs exposed to live Rlow and Rhigh as well as 
LAMPs from both strains differentially regulated several genes. A total of 166, 43, 55 
and 38 genes were differentially regulated ≥ 5-fold in TECs within 1.5 hour of exposure 
to either live Rlow or Rhigh, or to 5µg/mL Rlow or Rhigh LAMPs respectively. 23 genes were 
commonly up-regulated ≥ 5-fold in TECs in all four exposure groups, which included IL-
1β, IL-6, IL-8, IL-12p40 and CCL-20. Gene ontology and pathway analyses identified 
genes from several ontological categories and pathways to be up-regulated. Also 
exposure to viable Rlow resulted in differential expression of 110 unique genes by a factor 
of ≥ 5- fold.  
Kinetic analysis of 1β, IL-6, IL-8, IL-12p40, CCL-20 and NOS-2 identified their peak 
expression at 1.5 or 6 hours reducing significantly by 24 hours, suggesting these act as 
early responders to M. gallisepticum infection in context of epithelial cells. Also live Rlow 
was significantly more efficient in up-regulating expression of these genes when 
compared to Rhigh or LAMPs from both strains. 
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When gene expression in TECs after exposure to LAMPs in presence of various 
signaling inhibitors was analyzed, expression of all six genes reduced significantly in 
presence of a TLR-2/4 inhibitor but not TLR-4 inhibitor alone. In presence of a NF-κB 
inhibitor, gene expression reduced to baseline levels. Preliminary studies on various 
LAMP fractions and their role in up-regulating IL-1β from TECs identified possible 
important role of VlhA 3.03 and MslA.  
This study also analyzed for host regulatory mechanisms acting against lipoprotein 
and live mycoplasma mediated inflammatory gene up-regulation.  A regulatory micro 
RNA, miRNA146a was found to be up-regulated over time during exposure to live 
mycoplasma and negatively correlated with expression of pro-inflammatory genes.  
Therefore taken together this study suggest that M. gallisepticum lipid associated 
lipoproteins up-regulate inflammatory genes from tracheal epithelial cells via ligation to 
TLR-2 in a NF-κB dependent pathway. Live virulent strain Rlow however, was found to 
be significantly more efficient in differential gene expression from TECs. This study also 
identified presence of host compensatory mechanisms that most likely aid in regulating 
this pro-inflammatory response.   
Although this study identified the role of M. gallisepticum LAMPs in initiating 
inflammatory response from TECs in vitro and ex vivo, more detailed in vivo studies are 
required to elucidate similarities and/or differences in this response within a live host.  It 
would also be important to identify specific lipoproteins involved in this response leading 
to a better understanding of M. gallisepticum virulence factors and host inflammatory 
responses.    
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4.2 Study II 
Whereas the first study identified role of live M. gallisepticum and their lipid 
associated membrane proteins in differentially regulating inflammatory genes from host 
respiratory epithelial cells, the second study was sought to identify how this interaction 
might play a role in the inflammatory response observed during infection.  
The results of this study indicated that interaction of tracheal epithelial cells with the 
virulent Rlow strain lead to significantly more efficient in macrophage chemotaxis when 
compared to the non-virulent Rhigh strain.  Expression of various chemokine and cytokine 
genes were analyzed, including IFN-γ, IL-1β, IL-6, IL-8, CCL-20, MIP-1β, CXCL-13 
and RANTES. IFN-γ expression did not differ significantly in macrophages (HD-11) co-
cultured with M. gallisepticum exposed tracheal epithelial cells, but expression of rest of 
the genes were significantly up-regulated. Expression of all analyzed genes were also 
observed to be significantly higher in HD-11 cells co-cultured with TECs exposed to Rlow 
compared to Rhigh at least during two or more time point.  
The study also analyzed the effect of live M. gallisepticum on HD-11 cells. Similarly 
as the co-culture study, chemokine and cytokine genes were significantly up-regulated 
during both exposures. But Rlow did not show higher efficacy compared to Rhigh, in fact in 
certain cases Rhigh was found to be more efficient. It was also observed that various MOI 
of mycoplasma were almost equally capable in up-regulating these genes.  
During kinetic analysis of the chemokine and cytokine genes the average trend 
showed, that the cytokine genes peaked at 6 hours and significantly reduced by 24 hours, 
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but the chemokine genes except CCL-20 peaked at 24 hours or had a sustained 
expression after 6 hours especially in presence of Rlow.  
Therefore this study supports the notion that interaction of M. gallisepticum with host 
respiratory epithelial cells leads to macrophage chemotaxis and up-regulation of 
inflammatory genes. The observation that virulent strains are more efficient in both these 
processes may also explain why these strains lead to a severe inflammatory response and 
the non-virulent strains fail to do so. However since during exposure of macrophages to 
live mycoplasma, virulent strains fail to show higher efficacy compared to a non-virulent 
strain, might indicate irrelevance to what is actually is observed in vivo, and suggest that 
mycoplasmal invasion of epithelial cells might not be required for precipitation of the 
inflammatory response. The observed kinetic trend of chemokine and cytokine genes may 
also indicate the severe immunopathology associated with M. gallisepticum infection in 
chickens without successful clearance of the pathogen.  
But it should be noted that this research had certain limitations. First these studies 
were done in vitro to characterize involvement of each cell type in the inflammatory 
process during M. gallisepticum infection and did not involve any in vivo models. 
Therefore more detailed in vivo studies are required to confirm these findings and better 
understand the cellular and molecular events during M. gallisepticum pathogenesis. Other 
limitations to this study include usage of a macrophage cell line and we should point out 
that a cell line may not respond the same way as primary cells and also may not be 
similar to what would be observed in vivo.  
Finally, all our studies analyzed mRNA expression, but abundance of mRNA in 
cytosol may not absolutely correlate with protein expression as up to a 40% variation in 
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protein concentration has been observed. Besides post transcriptional and post 
translational modifications play a key role in protein expression and release. This 
observation has previously been made in mycoplasma literature. A cytadhesion deficient 
non-virulent M. pneumonia strain was found to up-regulate mRNA expression of IL-1β in 
monocytes at a similar level as a virulent strain but lacked release of mature IL-1β like 
the virulent strain. This was dependent on caspase-1 mediated post translational 
processing [1, 2]. Therefore further analyses of protein expression of the chemokine and 
cytokine genes are required to make a stronger correlation to the inflammatory response 
observed during M. gallisepticum infection.  
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Figure 1: Epithelial Surface Localization of M. gallisepticum 
 
In-situ hybridization of M.gallisepticum 16S riboprobe in paraffin embedded chicken 
tracheal ring, 4 day post M. gallisepticum exposure at 400X magnification. Dark pink 
staining of the left figure indicates localization of mycoplasmas. No sub-epithelial 
mycoplasma could be detected.  
 
 
